<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005508.pub2" GROUP_ID="PVD" ID="764003122212094553" MERGED_FROM="" MODIFIED="2013-09-11 11:46:33 +0100" MODIFIED_BY="Cathryn Broderick" REVIEW_NO="532" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2013-09-11 11:46:33 +0100" MODIFIED_BY="Cathryn Broderick">
<TITLE>Beta blockers for peripheral arterial disease</TITLE>
<CONTACT MODIFIED="2013-09-11 11:46:33 +0100" MODIFIED_BY="Cathryn Broderick"><PERSON ID="15726" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Anthony</FIRST_NAME><LAST_NAME>Da Silva</LAST_NAME><POSITION>Consultant Surgeon</POSITION><EMAIL_1>tony.dasilva@new-tr.wales.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Wrexham Maelor Hospital</ORGANISATION><ADDRESS_1>Croesnewydd Road</ADDRESS_1><CITY>Wrexham</CITY><ZIP>LL13 7TD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1978 725124</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-09-11 11:46:33 +0100" MODIFIED_BY="Cathryn Broderick"><PERSON ID="B0C1272482E26AA200F0756D8CF5EFA8" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Sharath Chandra Vikram</FIRST_NAME><LAST_NAME>Paravastu</LAST_NAME><POSITION>Clinical Lecturer in Vascular Surgery</POSITION><EMAIL_1>sharathparavastu@googlemail.com</EMAIL_1><ADDRESS><DEPARTMENT>Academic Vascular Unit</DEPARTMENT><ORGANISATION>The University of Sheffield</ORGANISATION><ADDRESS_1>Regent Court, 30 Regent Street</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S1 4DA</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 114 222 6390</PHONE_1><FAX_1>+44 114 272 4095</FAX_1></ADDRESS></PERSON><PERSON ID="18469" ROLE="AUTHOR"><FIRST_NAME>Derick</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Mendonca</LAST_NAME><POSITION>Surgical Specialist Registrar</POSITION><EMAIL_1>derickmen@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Plastic and Reconstructive Surgery</DEPARTMENT><ORGANISATION>Bangalore Baptist Hospital</ORGANISATION><CITY>Bangalore</CITY><COUNTRY CODE="IN">India</COUNTRY></ADDRESS></PERSON><PERSON ID="15726" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Anthony</FIRST_NAME><LAST_NAME>Da Silva</LAST_NAME><POSITION>Consultant Surgeon</POSITION><EMAIL_1>tony.dasilva@new-tr.wales.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Wrexham Maelor Hospital</ORGANISATION><ADDRESS_1>Croesnewydd Road</ADDRESS_1><CITY>Wrexham</CITY><ZIP>LL13 7TD</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1978 725124</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-08-14 14:20:43 +0100" MODIFIED_BY="Heather Maxwell">
<UP_TO_DATE>
<DATE DAY="15" MONTH="3" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="3" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2013-08-07 13:28:28 +0100" MODIFIED_BY="Heather Maxwell">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-08-07 13:28:28 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>Searches rerun, no new studies included, four new studies excluded. Risk of bias tables completed and methods and abstract updated to reflect current Cochrane standards. Conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-08-07 08:32:21 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="2" MONTH="8" YEAR="2013"/>
<DESCRIPTION>
<P>Searches rerun, no new studies included, four new studies excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-08-02 14:22:29 +0100" MODIFIED_BY="Heather Maxwell">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2013-08-02 14:22:29 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="2" YEAR="2010"/>
<DESCRIPTION>
<P>Feedback and review author's reply added to review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-16 15:45:28 +0000" MODIFIED_BY="Heather Maxwell">
<DATE DAY="3" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-08-07 14:27:48 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2013-08-07 14:27:48 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-08-07 14:27:48 +0100" MODIFIED_BY="[Empty name]">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The Cochrane PVD Group editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-09-11 11:36:14 +0100" MODIFIED_BY="Heather Maxwell">
<SUMMARY MODIFIED="2013-09-05 14:23:48 +0100" MODIFIED_BY="Heather  Maxwell">
<TITLE MODIFIED="2008-07-03 11:57:51 +0100" MODIFIED_BY="Heather  Maxwell">Beta blockers for peripheral arterial disease</TITLE>
<SUMMARY_BODY MODIFIED="2013-09-05 14:23:48 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Intermittent claudication, the most common symptom of atherosclerotic peripheral arterial disease, results from decreased blood flow to the legs during exercise. Beta blockers, a large group of drugs, have been shown to decrease death among people with high blood pressure and coronary artery disease and are used to treat various disorders. They reduce heart activity but can also inhibit relaxation of smooth muscle in blood vessels, bronchi and the gastrointestinal and genitourinary tracts. The non-selective beta blockers propranolol, timolol and pindolol are effective at all beta-adrenergic sites in the body, whereas other beta blockers, such as atenolol and metoprolol, are selective for the heart.</P>
<P>Optimal therapy for people with coronary artery disease or hypertension and intermittent claudication is controversial because of the presumed peripheral blood flow consequences of beta blockers, which lead to worsening of symptoms.</P>
<P>Currently, no evidence from randomised controlled trials suggests that beta blockers adversely affect walking distance in people with intermittent claudication, and beta blockers should be used with caution, if clinically indicated. The review authors identified six randomised controlled trials that involved a total of only 119 people with mild to moderate peripheral arterial disease. The beta blockers studied were propranolol, pindolol, atenolol and metoprolol. None of the trials showed clear worsening effects of beta blockers on time to claudication, claudication distance and maximal walking distance as measured on a treadmill, nor on calf blood flow, calf vascular resistance and skin temperature, when compared with placebo. Trial investigators reported no adverse events or issues regarding taking the beta blockers studied.</P>
<P>Most of the trials were over 20 years old and reported findings between 1980 and 1991. All were small and of poor quality. The drugs were administered over a short time (10 days to two months), and most of the outcome measures were reported in single studies. Additional drugs&#65293;calcium channel blockers and combined alpha and beta blockers&#65293;were given during some of the trials.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-09-05 14:21:19 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-09-05 14:16:20 +0100" MODIFIED_BY="[Empty name]">
<P>Beta (&#946;) blockers are indicated for use in coronary artery disease (CAD). However, optimal therapy for people with CAD accompanied by intermittent claudication has been controversial because of the presumed peripheral haemodynamic consequences of beta blockers, leading to worsening symptoms of intermittent claudication. This is an update of a review first published in 2008.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-09-05 14:16:33 +0100" MODIFIED_BY="[Empty name]">
<P>To quantify the potential harmful effects of beta blockers on maximum walking distance, claudication distance, calf blood flow, calf vascular resistance and skin temperature when used in patients with peripheral arterial disease (PAD).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-09-05 14:18:25 +0100" MODIFIED_BY="[Empty name]">
<P>For this update,<I> </I>the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched March 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library,</I> 2013, Issue 2).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-09-05 14:18:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) evaluating the role of both selective (&#946;1) and non-selective (&#946;1 and &#946;2) beta blockers compared with placebo. We excluded trials that compared different types of beta blockers.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-09-05 14:19:13 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures were claudication distance in metres, time to claudication in minutes and maximum walking distance in metres and minutes (as assessed by treadmill).</P>
<P>Secondary outcome measures included calf blood flow (mL/100 mL/min), calf vascular resistance and skin temperature (ºC).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-09-05 14:20:48 +0100" MODIFIED_BY="[Empty name]">
<P>We included six RCTs that fulfilled the above criteria, with a total of 119 participants. The beta blockers studied were atenolol, propranolol, pindolol and metoprolol. All trials were of poor quality with the drugs administered over a short time (10 days to two months). None of the primary outcomes were reported by more than one study. Similarly, secondary outcome measures, with the exception of vascular resistance (as reported by three studies), were reported, each by only one study. Pooling of such results was deemed inappropriate. None of the trials showed a statistically significant worsening effect of beta blockers on time to claudication, claudication distance and maximal walking distance as measured on a treadmill, nor on calf blood flow, calf vascular resistance and skin temperature, when compared with placebo. No reports described adverse events associated with the beta blockers studied.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-09-05 14:21:19 +0100" MODIFIED_BY="[Empty name]">
<P>Currently, no evidence suggests that beta blockers adversely affect walking distance, calf blood flow, calf vascular resistance and skin temperature in people with intermittent claudication. However, because of the lack of large published trials, beta blockers should be used with caution, if clinically indicated.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-09-11 11:36:14 +0100" MODIFIED_BY="Heather Maxwell">
<BACKGROUND MODIFIED="2013-09-05 14:31:15 +0100" MODIFIED_BY="Heather Maxwell">
<CONDITION MODIFIED="2013-09-05 14:24:16 +0100" MODIFIED_BY="[Empty name]">
<P>Intermittent claudication, the most common symptom of atherosclerotic peripheral arterial disease (<LINK REF="REF-Hiatt-2001" TYPE="REFERENCE">Hiatt 2001</LINK>), reflects decreased blood flow to the extremities during exercise (<LINK REF="REF-Lassila-1986" TYPE="REFERENCE">Lassila 1986</LINK>). The incidence of intermittent claudication increases with advancing age, cigarette smoking, impaired glucose tolerance and hypertension (<LINK REF="REF-Hughson-1978" TYPE="REFERENCE">Hughson 1978</LINK>). Men are twice as likely as women to be affected by intermittent claudication (<LINK REF="REF-Kannel-1985" TYPE="REFERENCE">Kannel 1985</LINK>).</P>
<P>Patients with peripheral arterial disease (PAD) have increased rates of mortality due to concurrent coronary artery disease and hypertension (<LINK REF="REF-Criqui-1985" TYPE="REFERENCE">Criqui 1985</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-09-05 14:27:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>Beta (&#946;) blockers were thought to decrease all-cause and cardiovascular mortality and were used as a first-line medication for primary hypertension. However, recent evidence is counter-intuitive to this and has demonstrated that beta blockers are less efficacious than placebo, thiazides or angiotensin-converting enzyme inhibitors in the treatment of primary hypertension (<LINK REF="REF-Bangalore-2007" TYPE="REFERENCE">Bangalore 2007</LINK>; <LINK REF="REF-Lavie-2009" TYPE="REFERENCE">Lavie 2009</LINK>; <LINK REF="REF-Lindholm-2005" TYPE="REFERENCE">Lindholm 2005</LINK>; <LINK REF="REF-Wiysonge-2007" TYPE="REFERENCE">Wiysonge 2007</LINK>; <LINK REF="REF-Wright-2009" TYPE="REFERENCE">Wright 2009</LINK>). Further, beta blockers are associated with a higher incidence of all-cause and cardiovascular mortality compared with other antihypertensive medication. Furthermore, a recent Cochrane review showed that beta blockers fail to improve cardiovascular mortality even when used as a second-line therapy for treatment of hypertension (<LINK REF="REF-Chen-2010" TYPE="REFERENCE">Chen 2010</LINK>). Currently, beta blockers are indicated in the treatment of angina and acute myocardial infarction and heart failure (<LINK REF="REF-Javed-2009" TYPE="REFERENCE">Javed 2009</LINK>; <LINK REF="REF-NICE-2010" TYPE="REFERENCE">NICE 2010</LINK>). In addition, they are used  to treat arrhythmias (variations in the normal rhythm of the heartbeat), migraine headaches, essential tremors, thyrotoxicosis (excessive production of thyroid hormones), glaucoma, anxiety and various other disorders.</P>
<P>Beta blockers make up a large group of drugs, and although all are competitive inhibitors of &#946; receptors, they may have additional pharmacodynamic properties. In addition to increasing the force and rate of myocardial contraction, &#946;1 receptors increase conduction velocity through the atrioventricular (AV) node. Beta1 blockade, therefore, reduces heart rate, blood pressure, myocardial contractility and myocardial oxygen consumption. Beta2 receptor blockade inhibits relaxation of smooth muscle in blood vessels, bronchi and the gastrointestinal and genitourinary tracts. In addition, &#946;2 blockade inhibits the breakdown of glycogen (the main carbohydrate storage compound) to glucose (glycogenolysis) and the formation of sugar from protein and fat in the absence of glucose or carbohydrate (gluconeogenesis). Non-specific beta blockers such as propranolol, timolol, nadolol, and pindolol demonstrate equal affinity for both &#946;1 and &#946;2 receptors. Commonly used cardioselective (&#946;1) blockers are atenolol and metoprolol.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-09-05 14:30:17 +0100" MODIFIED_BY="Heather  Maxwell">
<P>In general, blockade of &#946; receptors results in decreased production of intracellular cyclic adenosine monophosphate (cAMP), with resultant blunting of the multiple metabolic and cardiovascular effects of circulating catecholamines. Beta blockers are indicated for use after myocardial infarction (MI). It has been shown that therapy initiated within 12 hours of MI decreases the rate of in-hospital cardiovascular mortality by 13% to 15% (<LINK REF="REF-MIAMI-trial" TYPE="REFERENCE">MIAMI trial</LINK>). Beta blockers have also been indicated for use in patients with continuing or recurrent ischaemic pain, tachyarrhythmias (rapid heart rates associated with an irregularity in the normal heart rhythm) and non&#65293;ST-elevation MI (<LINK REF="REF-ACCF_x002f_AHA-2012" TYPE="REFERENCE">ACCF/AHA 2012</LINK>).</P>
<P>Optimal therapy for coronary artery disease or hypertension accompanied by intermittent claudication has been controversial because of presumed peripheral haemodynamic consequences of beta blockers that could lead to worsening of symptoms in patients with PAD (<LINK REF="REF-George-1974" TYPE="REFERENCE">George 1974</LINK>). This has been attributed to decreased cardiac output and unopposed alpha (&#945;)-adrenergic drive.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-09-05 14:31:15 +0100" MODIFIED_BY="Heather  Maxwell">
<P>It is well known that acute lowering of blood pressure is contraindicated in critical ischaemia. However, the effect of lowering of blood pressure in people with intermittent claudication is not known. Beta blockers are contraindicated in severe PAD (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). The aim of this review is to gather evidence for the contraindication of beta blockers in people with intermittent claudication.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-09-05 14:31:26 +0100" MODIFIED_BY="[Empty name]">
<P>To quantify the potential harmful effects of beta blockers on maximum walking distance, claudication distance, calf blood flow, calf vascular resistance and skin temperature when used in patients with PAD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-09-05 14:39:56 +0100" MODIFIED_BY="Heather  Maxwell">
<SELECTION_CRITERIA MODIFIED="2013-09-05 14:33:57 +0100" MODIFIED_BY="Heather  Maxwell">
<CRIT_STUDIES MODIFIED="2013-09-05 14:32:14 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing beta blockers and placebo in participants with PAD.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-09-05 14:32:38 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Patients with moderate to severe PAD, with or without additional co-morbidity (an additional disease or condition, for example, diabetes mellitus), were included. Peripheral arterial disease was defined as a typical history of intermittent claudication and reduced ankle brachial pressure index (ABPI)&#65293;less than 0.9.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-09-05 14:32:51 +0100" MODIFIED_BY="Heather  Maxwell">
<P>We included studies that used selective beta blockers (&#946;1) and non-selective beta blockers (&#946;1 and &#946;2). We excluded studies using some beta blockers with additional alpha (&#945;) blocking properties (for example, labetalol).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-09-05 14:33:57 +0100" MODIFIED_BY="Heather  Maxwell">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-09-05 14:33:06 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures considered for this review were initial claudication distance in metres, time to claudication in minutes and maximal walking distance in metres and minutes (as assessed by treadmill).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-09-05 14:33:57 +0100" MODIFIED_BY="[Empty name]">
<P>Secondary outcome measures included calf blood flow (mL/100 mL/min), calf vascular resistance and skin temperature (ºC). Mortality data and complications associated with the use of beta blockers, such as development of critical ischaemia, cardiovascular morbidity and mortality; all-cause mortality; and drug withdrawal, were also recorded for participants with stable PAD.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-09-05 14:35:13 +0100" MODIFIED_BY="Heather  Maxwell">
<P>No restrictions on language of publication were applied.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-09-05 14:35:00 +0100" MODIFIED_BY="[Empty name]">
<P>For this update,<I> </I>the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched March 2013) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 2; part of <I>The Cochrane Library</I>, <A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL and AMED and handsearching of relevant journals. The full list of the databases, journals and conference proceedings that have been searched and the search strategies used are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Peripheral Vascular Diseases Group module in <I>The Cochrane Library </I>(<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-09-05 14:35:13 +0100" MODIFIED_BY="[Empty name]">
<P>We searched bibliographies of all identified research articles and review articles.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-09-05 14:39:56 +0100" MODIFIED_BY="Heather  Maxwell">
<STUDY_SELECTION MODIFIED="2013-09-05 14:36:11 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>All three review authors independently reviewed abstracts of potential trials involving beta blockers in PAD. We obtained full papers for those fulfilling the relevant criteria or when clarification was required. We excluded trials that compared different types of beta blockers.</P>
<P>Studies that met the inclusion criteria were independently selected by SCVP and DAM, and this process was overseen by ADS. No disagreements among SCVP and DAM regarding inclusion were reported; however, both could not decide on inclusion of one study, and this decision was made by ADS.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-09-05 14:36:37 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>SCVP and DAM independently extracted data from the included studies using the proforma designed by the Cochrane PVD Group.</P>
<P>Some of the results, for example, calf blood flow (<LINK REF="STD-Hiatt-1985" TYPE="STUDY">Hiatt 1985</LINK>; <LINK REF="STD-Lepantalo-1984a" TYPE="STUDY">Lepantalo 1984a</LINK>; <LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK>), claudication and maximal walking distance (<LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK>), were presented only as graphs, hence we excluded them from the analyses.</P>
<P>Vascular resistance is described in arbitrary units. The review authors calculated vascular resistance by dividing mean arterial blood pressure by calf blood flow.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-09-05 14:36:57 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>All three review authors independently assessed the methodological quality of selected trials using the Cochrane 'Risk of bias' tool provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(version 5.1.0) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The results for each included trial are summarised in the 'Risk of bias' tables.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-09-05 14:37:24 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>We planned to use odds ratio (OR) with 95% confidence interval (CI) for dichotomous variables and mean difference (MD) with 95% CI for continuous variables.</P>
<P>Meta-analyses were not performed, hence data from individual trials are discussed and presented.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-09-05 14:37:50 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Each participant was considered an individual unit of analysis for this review, as meta-analyses were not performed. However, in future reviews, if new trials have been published, for cross-over trials, when available, paired data will be considered to avoid unit of analysis error. If it becomes difficult to identify data clearly, individual participant data will be considered for meta-analysis, but results will be presented with caution.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-09-05 14:38:10 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Some key data were missing from some of the trials. As they were old trials, study co-ordinators could not be contacted to obtain more information. With regards to some trials, details of standard deviation were calculated from the provided standard error and mean, as discussed by <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-09-05 14:38:58 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Variability in participants, interventions and outcomes was considered in the assessment of clinical heterogeneity. As a meta-analysis was not performed, statistical heterogeneity was not relevant.</P>
<P>If new trials are included in future updates of this review, when possible, we will perform statistical analysis according to the statistical guidelines for review authors put forth by the Cochrane PVD Group. We will assess the degree of heterogeneity amongst trials by using the I<SUP>2 </SUP>statistic according to the formula I<SUP>2</SUP> = 100% × (Q - degrees of freedom)/Q, where Q is the Chi<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We will present a summary statistic for each outcome using a fixed-effect model for homogenous data and a random-effects model for heterogenous data.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-09-05 14:39:15 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>The review authors intended to use funnel plots for publication bias; however, as no meta-analysis was performed, this could not be done. All studies were carefully assessed to look for selective reporting bias. Whilst no uniformity was observed in the results presented, outcome reporting was quite varied among trials.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-09-05 14:39:31 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Because data from the included studies were insufficient, meta-analysis was not performed. If new trials are included in future updates of this review, we will present a summary statistic for each outcome using a fixed-effect model for homogenous data and a random-effects model for heterogenous data.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-09-05 14:39:42 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Subgroup analysis was not feasible because data were insufficient; however, such an analysis will be carried out if sufficient data are provided by future trials.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-09-05 14:39:56 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>We planned to undertake sensitivity analyses to examine the stability of the results in relation to a number of factors, including study quality, the source of the data (published and unpublished) and participant type. Such analyses were not undertaken because sufficient data were lacking.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-09-05 14:52:12 +0100" MODIFIED_BY="Heather  Maxwell">
<STUDY_DESCRIPTION MODIFIED="2013-09-05 14:45:57 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-08-07 09:35:27 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-09-05 14:45:46 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>No additional studies are included in this update.</P>
<P>We have included six RCTs that fulfilled the inclusion criteria for this review (<LINK REF="STD-Clement-1980" TYPE="STUDY">Clement 1980</LINK>; <LINK REF="STD-Hiatt-1985" TYPE="STUDY">Hiatt 1985</LINK>; <LINK REF="STD-Lepantalo-1984a" TYPE="STUDY">Lepantalo 1984a</LINK>; <LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK>; <LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK>; <LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK>). Summary details of included studies are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>Various beta blockers were used and compared with placebo in the above-mentioned trials. Propranolol, atenolol and metoprolol were the most commonly evaluated beta blockers.</P>
<P>In a randomised, double-blind, placebo-controlled trial, <LINK REF="STD-Clement-1980" TYPE="STUDY">Clement 1980</LINK> evaluated the effects of propranolol (80 mg twice daily) and metoprolol (100 mg twice daily) on claudication and maximal walking times in participants with chronic intermittent claudication. In this cross-over trial, 10 participants with chronic intermittent claudication were given a wash-out period with placebo for four weeks and were subsequently randomly assigned to receive metoprolol, propranolol or placebo, each for two months.</P>
<P>
<LINK REF="STD-Hiatt-1985" TYPE="STUDY">Hiatt 1985</LINK> compared the effects of metoprolol (50 mg) and propranolol (40 mg) with those of placebo on calf blood flow and vascular resistance. In this randomised, double-blind, placebo-controlled trial, 19 participants with chronic stable intermittent claudication received placebo in the run-in phase for three weeks. Participants were later randomly assigned to receive either metoprolol or propranolol for two weeks. Subsequently, they were administered placebo for two weeks before the cross-over phase. As in the earlier studies, calf blood flow was measured using venous occlusion plethysmography.</P>
<P>
<LINK REF="STD-Lepantalo-1984a" TYPE="STUDY">Lepantalo 1984a</LINK> studied the effects of metoprolol and methyldopa on calf blood flow and vascular resistance in participants with peripheral vascular disease. In this randomised, double-blind, placebo-controlled trial, 14 participants were given placebo in the run-in phase for three weeks and were subsequently randomly assigned to receive metoprolol (100 to 200 mg), methyldopa (500 to 1000 mg) or placebo, each for three weeks. Calf blood flow was measured using venous occlusion plethysmography.</P>
<P>In another randomised, double-blind, placebo-controlled trial, <LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK> evaluated the effects of propranolol (80 mg), pindolol (5 mg), labetalol (200 mg), labetalol (400 mg) and placebo on hyperaemic calf blood flow, skin temperature and vascular resistance in seven participants with hypertension and chronic intermittent claudication. All drugs were administered for 10 days.</P>
<P>
<LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK> administered atenolol (100 mg), labetalol (200 mg), pindolol (5 mg), captopril (25 mg) and placebo to a total of 20 participants and studied their effects on mean blood pressure, calf blood flow, mean pain-free walking distance and mean maximal walking distance. All participants received placebo for a month as an initial wash-out phase. Later, they were randomly assigned to receive atenolol, labetalol, pindolol, captopril or placebo, each for one month. Calf blood flow was measured using venous occlusion plethysmography, and walking distances were assessed using a treadmill.</P>
<P>
<LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK> evaluated the effects of atenolol (50 mg), nifedipine (20 mg) and a combination of atenolol and nifedipine, as well as placebo, on skin temperature and walking distance in a total of 49 participants, who were randomly assigned after a run-in phase with placebo. In this cross-over trial, drugs were administered, each for four weeks. No wash-out period preceded cross-over of participants.</P>
<P>None of the primary outcomes were reported by more than one study. Similarly, secondary outcome measures, with the exception of vascular resistance (as reported by three studies), were reported, each by only one study. Pooling of such results was deemed inappropriate, hence results of individual series are presented.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-09-05 14:45:57 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>An additional four studies (<LINK REF="STD-Diehm-2011" TYPE="STUDY">Diehm 2011</LINK>; <LINK REF="STD-Ehrly-1987" TYPE="STUDY">Ehrly 1987</LINK>; <LINK REF="STD-Espinola_x002d_Klein-2011" TYPE="STUDY">Espinola-Klein 2011</LINK>; <LINK REF="STD-van-de-Ven-1994" TYPE="STUDY">van de Ven 1994</LINK>) were excluded in this update, making a total of 22 excluded studies, with the reasons stated in the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-09-05 14:48:06 +0100" MODIFIED_BY="[Empty name]">
<P>Moderate to high risk of bias was seen in the included trials, as most of the methodological details, especially details on method of randomisation, could not be obtained from trial authors. Further details are provided in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2013-09-05 14:46:31 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Details on method of randomisation was mentioned only in <LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK> (randomisation codes) and <LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK> (computer randomisation).</P>
<P>Allocation concealment for most trials was unclear because of lack of reporting. <LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK> reported that the study tablets were dispensed monthly by hospital staff, but no further details were provided.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-09-05 14:47:01 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Most trials were reported to be double-blinded; however, in <LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK>, an independent observer who was aware of the randomisation codes assessed symptoms of participants at each visit.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-09-05 14:47:10 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Whilst <LINK REF="STD-Clement-1980" TYPE="STUDY">Clement 1980</LINK>, <LINK REF="STD-Hiatt-1985" TYPE="STUDY">Hiatt 1985</LINK> and <LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK> used intention-to-treat analysis, it was unclear whether such analysis was undertaken in the remaining trials (<LINK REF="STD-Lepantalo-1984a" TYPE="STUDY">Lepantalo 1984a</LINK>; <LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK>; <LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK>). These were therefore judged to be at unclear risk of bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-09-05 14:47:27 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>All trials (<LINK REF="STD-Clement-1980" TYPE="STUDY">Clement 1980</LINK>; <LINK REF="STD-Hiatt-1985" TYPE="STUDY">Hiatt 1985</LINK>; <LINK REF="STD-Lepantalo-1984a" TYPE="STUDY">Lepantalo 1984a</LINK>; <LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK>; <LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK>; <LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK>) reported their predetermined outcomes and therefore were judged to be at low risk of bias. Outcomes were quite varied, and the method of reporting differed between trials such that a meta-analysis could not be performed.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-09-05 14:48:06 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Details regarding cross-over were unclear in the <LINK REF="STD-Clement-1980" TYPE="STUDY">Clement 1980</LINK> trial, hence the potential for other bias exists. In the <LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK> trial, exclusion criteria were unclear, as were losses to follow-up. No suggestions can be made regarding other potential sources of bias in the remaining trials (<LINK REF="STD-Hiatt-1985" TYPE="STUDY">Hiatt 1985</LINK>; <LINK REF="STD-Lepantalo-1984a" TYPE="STUDY">Lepantalo 1984a</LINK>; <LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK>; <LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-09-05 14:52:12 +0100" MODIFIED_BY="Heather  Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">Claudication time</HEADING>
<P>One trial evaluated claudication time (<LINK REF="STD-Clement-1980" TYPE="STUDY">Clement 1980</LINK>). In this study, propranolol and metoprolol were compared with placebo. Mean claudication times were 5.20 minutes (standard deviation (SD) 2.25), 4.90 minutes (SD 2.04) and 4.53 minutes (SD 1.43) with propranolol, metoprolol and placebo, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Maximum walking time</HEADING>
<P>One trial evaluated maximum walking time (<LINK REF="STD-Clement-1980" TYPE="STUDY">Clement 1980</LINK>). Propranolol and metoprolol were compared with placebo. Mean maximal walking times were 8.18 minutes (SD 2.54), 8.18 minutes (SD 2.47) and 7.75 minutes (SD 2.20) with propranolol, metoprolol and placebo, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Claudication distance</HEADING>
<P>Only one trial evaluated claudication distance (<LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK>) and compared atenolol with placebo. Mean claudication distance was 62.6 metres for those who received atenolol versus 66.5 metres for those in the placebo group. The author reported a mean change reduction of 6% (95% CI 1% to -13%), which was considered to be clinically and statistically insignificant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Maximum walking distance</HEADING>
<P>
<LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK> evaluated maximum walking distance while comparing atenolol with placebo. Maximum walking distances with atenolol and placebo were 110.8 metres and 113.8 metres, respectively. The author reported a mean change reduction of 2% (95% CI 4% to -8%), which was considered to be clinically and statistically insignificant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Calf blood flow after exercise</HEADING>
<P>
<LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK> compared the effects of atenolol and pindolol with those of placebo on calf blood flow after exercise. Mean calf blood flow after exercise was 25.5 (SD 15.6), 20.1 (SD 10.2) and 29.9 (SD 17.8) mL/dL/min with atenolol, pindolol and placebo, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Calf vascular resistance</HEADING>
<P>The effects of propranolol and pindolol versus those of placebo on vascular resistance after reactive hyperaemia were evaluated in one trial (<LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK>). Vascular resistance was 2.5 units (SD 1.2), 2.1 units (SD 1.3) and 2.1 units (SD 1.3) with propranolol, pindolol and placebo, respectively.</P>
<P>The effect of metoprolol on calf vascular resistance was evaluated by <LINK REF="STD-Lepantalo-1984a" TYPE="STUDY">Lepantalo 1984a</LINK>. Results showed vascular resistance to be 1.7 units (SD 0.9) with metoprolol and 1.5 units (SD 1.0) with placebo.</P>
<P>
<LINK REF="STD-Hiatt-1985" TYPE="STUDY">Hiatt 1985</LINK> also compared the effect of metoprolol on vascular resistance after exercise. Vascular resistance was 11.5 units (SD 4.7) and 11.2 units (SD 4.4) for metoprolol and placebo, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Skin temperature</HEADING>
<P>The effects of propranolol and pindolol on skin temperature were evaluated in one trial (<LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK>). Mean skin temperature was 24.9°C (SD 3.8), 25.5°C (SD 4.0) and 27°C (SD 4.1) with propranolol, pindolol and placebo, respectively.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>For all of the trials that we reviewed, no reports described adverse events related to the use of beta blockers, including critical ischaemia, cardiovascular morbidity and mortality. These trials described no issues regarding participant compliance with medication.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-09-11 11:36:14 +0100" MODIFIED_BY="Heather  Maxwell">
<SUMMARY_OF_RESULTS MODIFIED="2013-09-05 14:55:34 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>This systematic review identified six randomised, double-blind, placebo-controlled, cross-over trials with a total of 119 participants. Most were small trials that recruited between 10 and 20 participants, and the largest study enrolled 49 participants (<LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK>).</P>
<P>None of the trials showed statistically significant worsening effects for beta blockers on the primary or secondary outcomes in participants with claudication. All trials were of poor quality, with the drugs administered over a short time (10 days to two months).</P>
<P>Investigators in the trial by Clement (<LINK REF="STD-Clement-1980" TYPE="STUDY">Clement 1980</LINK>) when using propranolol did not demonstrate a statistically significant decrease in claudication time or maximum walking time. This was a small trial that included only 10 participants. Details and data regarding the cross-over phase were unclear.</P>
<P>Lepantalo (<LINK REF="STD-Lepantalo-1984a" TYPE="STUDY">Lepantalo 1984a</LINK>) studied the effects of metoprolol on calf blood flow and vascular resistance. Results showed no deleterious effects in the metoprolol group. In this cross-over trial, participants were also randomly assigned to receive methyldopa, further confounding study results.</P>
<P>In another study, Lepantalo (<LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK>) randomly assigned a small number of participants to receive placebo, propranolol, pindolol and different strengths of labetalol (200 mg, 400 mg). The results, as described previously, showed no statistically significant worsening effects on the studied outcome measures. This small group of participants lacked proper randomisation and the cross-over phase was unclear, raising additional questions about the validity of study conclusions.</P>
<P>The overall effects of atenolol on claudication and maximal walking distances could not be estimated because sufficient data were lacking. In the trial by Solomon (<LINK REF="STD-Solomon-1991" TYPE="STUDY">Solomon 1991</LINK>), nifedipine (a calcium channel blocker) was also used in one of the drug groups, but no wash-out period was provided before the cross-over phase. This would have affected the outcome measures, which may not truly represent the effects of each individual drug.</P>
<P>A few limitations of this review are worth noting. Most of the trials were over 20 years old, and none of the reports supplied power calculations or a valid method of randomisation. Most important, no consistency of the inclusion criteria was noted between trials, and most of the included participants suffered from mild or moderate peripheral vascular disease. The duration of the course of beta blockers and of the cross-over phases varied between trials, and no wash-out periods were provided in some trials. In other trials, calcium channel blockers and combined alpha and beta blockers were used. Furthermore, primary outcome measures were available in only two trials, and complete outcome data were lacking in one of them. Finally, data were insufficient to pool individual results, hence individual data are presented. In conclusion, despite the inclusion of six RCTs, evidence supporting or refuting the use of beta blockers in peripheral arterial disease remains elusive.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-09-11 11:36:14 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>This review addressed whether evidence is available to suggest that beta blockers are harmful for patients with intermittent claudication. Not all outcome measures were available from all studies, and in some cases, trials reported incomplete data. These trials were very old, were not of good quality and consisted of only a minimal number of participants. The evidence, therefore, is not contemporary; however, no major adverse events resulting from the use of beta blockers were reported, which suggests that beta blockers may be used if required in patients with intermittent claudication. A cautious approach should be taken in patients with critical ischaemia.</P>
<P>All included trials were over 20 years old. Today, patients are increasingly aware of their health conditions, the importance of addressing their lifestyles and their co-morbidities are well managed. It is therefore possible that outcomes may vary considerably if the trials included in this review were to be repeated now. Therefore, the results of these trials should be interpreted with caution.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-09-05 14:57:16 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>The trials included in this review were not of high quality, and most failed to mention the randomisation technique or allocation concealment process used or losses to follow-up. Further, data were not clearly presented, and some of the outcomes of this review were not available in the included studies.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-09-05 14:58:05 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Two review authors (SCVP, DAM) independently assessed the articles for inclusion and exclusion criteria, thereby minimising the risk of any potential selection bias of articles. All data were extracted by using the proforma developed by the Cochrane PVD group. Data analysis was performed by two review authors (SCVP, DAM), and the senior review author (ADS) independently checked all results before final assessment and drafting of the manuscript.</P>
<P>Some results, for example, calf blood flow (<LINK REF="STD-Hiatt-1985" TYPE="STUDY">Hiatt 1985</LINK>; <LINK REF="STD-Lepantalo-1984a" TYPE="STUDY">Lepantalo 1984a</LINK>; <LINK REF="STD-Lepantalo-1985" TYPE="STUDY">Lepantalo 1985</LINK>), claudication distance and maximal walking distance (<LINK REF="STD-Roberts-1987" TYPE="STUDY">Roberts 1987</LINK>), were presented only as graphs, hence we excluded them from the analyses, as it was not possible to derive data suitable for inclusion.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-09-05 14:59:22 +0100" MODIFIED_BY="Cathryn  A Broderick">
<P>Miyajima et al (<LINK REF="REF-Miyajima-2004" TYPE="REFERENCE">Miyajima 2004</LINK>) conducted a review of RCTs<B> </B>that compared the effects of beta blockers versus placebo on intermittent claudication. Their review was slightly different in that they collated different beta blockers (although of the same type) versus placebo and found significant worsening of claudication distance with beta blockers. We do not agree with this method, as different drugs have different pharmacological properties. For example, pindolol and acebutolol have some intrinsic sympathomimetic activity as well (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). <LINK REF="REF-Miyajima-2004" TYPE="REFERENCE">Miyajima 2004</LINK> identified this and performed a subanalysis of beta blockers with and without intrinsic sympathomimetic activities and found no significant difference in walking distance. We think this grouping is also not appropriate because in the group without sympathomimetic activity, the authors included labetalol, which has an additional action of lowering peripheral vascular resistance that is not provided by the rest (<LINK REF="REF-BNF-2013" TYPE="REFERENCE">BNF 2013</LINK>). Although we disagree with the methods used by these review authors, their overall results suggested no significant effects of beta blockers on claudication time.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-09-05 15:00:15 +0100" MODIFIED_BY="Heather  Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2013-09-05 14:59:34 +0100" MODIFIED_BY="[Empty name]">
<P>The results of this systematic review have provided no strong evidence for or against the use of beta blockers in people with peripheral arterial disease. This has practice implications, as beta blockers play a significant role in averting major cardiovascular and perioperative complications. Thus the current advice that beta blockers should be used with caution in people with significant peripheral arterial disease still stands.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-09-05 15:00:15 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Currently, no evidence suggests that beta blockers adversely affect walking distance in people with intermittent claudication. However, no large published trials are available. Beta blockers should be used with caution, if clinically indicated, especially in cases of critical ischaemia for which acute lowering of blood pressure is contraindicated. The authors recommend that high-quality, randomised trials be conducted to evaluate the role of beta blockers in patients with mild, moderate and severe peripheral vascular disease.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-09-05 15:00:27 +0100" MODIFIED_BY="Heather  Maxwell">
<P>The authors sincerely thank Mrs Heather Maxwell and the editors of the Cochrane Peripheral Vascular Diseases Review Group for their support, and Dr Janet Wale of the Cochrane Consumer Network for providing a plain language summary. The authors would also like to acknowledge the efforts of the staff at The John Spalding Library at Wrexham Maelor Hospital in obtaining the papers for review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-09-05 15:00:59 +0100" MODIFIED_BY="Heather  Maxwell">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-09-05 15:00:34 +0100" MODIFIED_BY="Sharath C V  Paravastu">
<P>All three review authors contributed to selection of trials and assessment of their quality.</P>
<P>All three review authors independently extracted data. Anthony Da Silva resolved disagreements.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-09-05 15:01:12 +0100" MODIFIED_BY="[Empty name]">
<P>Risk of bias has been investigated using the 'Risk of bias' tool developed by The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), not by methods described by <LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK> and <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>, as originally planned in the protocol and in the previous review version.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-09-05 15:19:53 +0100" MODIFIED_BY="Heather Maxwell">
<STUDIES MODIFIED="2013-09-05 15:17:01 +0100" MODIFIED_BY="Heather  Maxwell">
<INCLUDED_STUDIES MODIFIED="2013-09-05 15:14:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Clement-1980" MODIFIED="2013-08-14 14:49:42 +0100" MODIFIED_BY="[Empty name]" NAME="Clement 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-08-14 14:27:55 +0100" MODIFIED_BY="Sharath C V  Paravastu" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bogaert MG, Clement DL</AU>
<TI>Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication</TI>
<SO>European Heart Journal</SO>
<YR>1983</YR>
<VL>4</VL>
<NO>3</NO>
<PG>203-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-14 14:49:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10. Clement D: Studies on the effect of alpha- and beta-adrenergic&lt;br&gt;blocking agents on the circulation in human limbs. Verh K Acad&lt;br&gt;Geneeskd Belg 42: 164, 1980&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-08-14 14:49:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Clement DL</AU>
<TI>Studies on the effect of alpha- and beta- adrenergic blocking agents on the circulation in human limbs</TI>
<SO>Verhandelingen Van De Koninklijke Academie voor Geneeskunde van Belgie</SO>
<YR>1980</YR>
<VL>XLII(3-4)</VL>
<NO>42</NO>
<PG>164-214</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiatt-1985" NAME="Hiatt 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiatt WR, Stoll S, Nies AS</AU>
<TI>Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease</TI>
<SO>Circulation</SO>
<YR>1985</YR>
<VL>72</VL>
<NO>6</NO>
<PG>1226-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepantalo-1984a" NAME="Lepantalo 1984a" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lepantalo M</AU>
<TI>Chronic effects of metoprolol and methyldopa on calf blood flow in intermittent claudication</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1984</YR>
<VL>18</VL>
<NO>1</NO>
<PG>90-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepantalo-1985" MODIFIED="2013-08-14 14:49:49 +0100" MODIFIED_BY="Sharath C V  Paravastu" NAME="Lepantalo 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-08-14 14:28:17 +0100" MODIFIED_BY="Sharath C V  Paravastu" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lepantalo M, Lindstorm BL, Totterman KJ</AU>
<TI>Adrenoreceptor blocking drugs and cold feet in intermittent claudication</TI>
<SO>VASA. Zeitschrift für Gefässkrankheiten</SO>
<YR>1986</YR>
<VL>15</VL>
<NO>2</NO>
<PG>135-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-14 14:49:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lepantalo M</AU>
<TI>Chronic effects of labetalol, pindolol, and propranolol on calf blood flow in intermittent claudication</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1985</YR>
<VL>37</VL>
<NO>1</NO>
<PG>7-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1987" NAME="Roberts 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A</AU>
<TI>Placebo controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>ii:</VL>
<NO>8560</NO>
<PG>650-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solomon-1991" MODIFIED="2013-09-05 15:14:37 +0100" MODIFIED_BY="[Empty name]" NAME="Solomon 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-09-05 15:14:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W</AU>
<TI>Beta-blockade and intermittent claudication: placebo controlled trial of atenolol, nifedipine and their combination</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>303</VL>
<NO>6810</NO>
<PG>1100-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-09-05 15:17:01 +0100" MODIFIED_BY="Heather  Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Aarts-1986" MODIFIED="2013-09-05 15:14:51 +0100" MODIFIED_BY="Dolores Matthews" NAME="Aarts 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-09-05 15:14:51 +0100" MODIFIED_BY="Dolores Matthews" NOTES="&lt;p&gt;Aarts PAMM. Banga JD. Van Houwelingen HC. et al. Increased red blood cell deformability due to isoxsuprine administration decreases platelet adherence in a perfusion chamber: A double-blind cross-over study in patients with intermittent claudication. [Journal] Blood. Vol. 67(5)(pp 1474-1481), 1986.&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 15:14:51 +0100" NOTES_MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aarts PA, Banga JD, van Houwelingen HC, Heethaar RM, Sixma JJ</AU>
<TI>Increased red blood cell deformability due to isoxsuprine administration decreases platelet adherence in a perfusion chamber: a double-blind cross-over study in patients with intermittent claudication</TI>
<SO>Blood</SO>
<YR>1986</YR>
<VL>67</VL>
<NO>5</NO>
<PG>1474-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bostrom-1986" NAME="Bostrom 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Bogaert MG. Clement DL. Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication. [Journal] European Heart Journal. Vol. 4(3)(pp 203-204), 1983.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bostrom PA, Janzon L, Ohlsson O, Westergren A</AU>
<TI>The effect of beta-blockade on leg blood flow in hypertensive patients with intermittent claudication</TI>
<SO>Angiology</SO>
<YR>1986</YR>
<VL>37</VL>
<NO>3 pt1</NO>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1998" NAME="Brown 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM</AU>
<TI>Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT)</TI>
<SO>Journal of Hypertension</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>12</NO>
<PG>2113-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4769"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diehm-1993" MODIFIED="2008-07-09 08:48:36 +0100" MODIFIED_BY="[Empty name]" NAME="Diehm 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-07-09 08:48:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diehm C, Jacobsen O, Amendt K</AU>
<TI>The effects of tertalolol on lipid profile</TI>
<SO>Cardiology</SO>
<YR>1993</YR>
<VL>83 Suppl 1</VL>
<PG>32-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diehm-2011" MODIFIED="2013-08-05 08:41:59 +0100" MODIFIED_BY="[Empty name]" NAME="Diehm 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-08-05 08:41:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diehm C, Pittrow D, Lawall H</AU>
<TI>Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication</TI>
<SO>Journal of Hypertension</SO>
<YR>2011</YR>
<VL>29</VL>
<PG>1448-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ehrly-1987" MODIFIED="2013-08-05 08:43:06 +0100" MODIFIED_BY="[Empty name]" NAME="Ehrly 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-08-05 08:43:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ehrly AM, Landgraf H, Saeger LK</AU>
<TI>Influence of propranolol and bunitrolol on muscular tissue oxygen pressure of patients with intermittent claudication and arterial hypertension</TI>
<SO>Die Medizinische Welt</SO>
<YR>1987</YR>
<VL>38</VL>
<PG>1052-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Espinola_x002d_Klein-2011" MODIFIED="2013-09-05 15:15:03 +0100" MODIFIED_BY="Sharath C V  Paravastu" NAME="Espinola-Klein 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-09-05 15:15:03 +0100" MODIFIED_BY="Sharath C V  Paravastu" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad MA, et al</AU>
<TI>Beta-blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial</TI>
<SO>Hypertension</SO>
<YR>2011</YR>
<VL>58</VL>
<NO>2</NO>
<PG>148-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forbes-1999" MODIFIED="2013-09-05 15:15:28 +0100" MODIFIED_BY="[Empty name]" NAME="Forbes 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-09-05 15:15:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forbes CD, Lowe GD, Maclaren M, Shaw BG, Dickinson JP, Keiffer G</AU>
<TI>Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta blocker and a calcium uptake antagonist</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>1999</YR>
<VL>25 Suppl 2</VL>
<PG>55-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iarussi-1977" MODIFIED="2013-08-07 09:17:56 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Iarussi 1977" YEAR="1977">
<REFERENCE MODIFIED="2013-08-07 09:17:56 +0100" MODIFIED_BY="Heather  Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iarussi D, Ferrante MR, Garofalo S, De Cristofaro M</AU>
<TI>Instrumental evaluation of the effects of a delayed-action preparation of a isoxsuprine on the peripheral circulation</TI>
<TO>Valutazione strumentale degli effetti sul circolo periferico di un preparato di isossisuprina ad azione protratta</TO>
<SO>La Clinica Terapeutica</SO>
<YR>1977</YR>
<VL>80</VL>
<NO>4</NO>
<PG>315-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karnik-1987" NAME="Karnik 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karnik R, Valentin A, Slany J</AU>
<TI>Different effects of beta-1-adrenergic blocking agents with ISA or without ISA on peripheral blood flow</TI>
<SO>Angiology</SO>
<YR>1987</YR>
<VL>38</VL>
<NO>4</NO>
<PG>296-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klieber-1986" MODIFIED="2013-09-05 15:15:47 +0100" MODIFIED_BY="Dolores Matthews" NAME="Klieber 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-09-05 15:15:47 +0100" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klieber M, Resch F</AU>
<TI>Comparative studies of the effect of a cardioselective and a non-cardioselective beta blocker on peripheral circulation in patients with arterial occlusive disease</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1986</YR>
<VL>98</VL>
<NO>3</NO>
<PG>70-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konecny-1986" MODIFIED="2013-09-05 15:16:19 +0100" MODIFIED_BY="[Empty name]" NAME="Konecny 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-09-05 15:16:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;The acute effect of celiprolol I.V. on the resting blood flow of calf and foot in healthy subjects and patients with peripheral arterial occlusive disease (PAOD)&lt;/p&gt;" NOTES_MODIFIED="2013-09-05 15:16:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Konecny U, Ehringer H, Rasser W, Koppensteiner R, Minar E, Wachter M</AU>
<TI>The acute effect of celiprolol I.V. on the resting blood flow of calf and foot in healthy subjects and patients with peripheral arterial occlusive disease (PAOD)</TI>
<SO>What is new in angiology? Trends and controversies</SO>
<YR>1986</YR>
<PG>541-2</PG>
<ED>Maurer PC, Becker HM, Heidrich H, Hoffmann G, Kriessmann A, Muller-Wiefel H, Pratorius C</ED>
<PB>Zuckschwerdt W</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lepantalo-1984b" NAME="Lepantalo 1984b" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lepantalo M, von Knorring J</AU>
<TI>Walking capacity of patients with intermittent claudication during chronic antihypertensive treatment with metoprolol and methyldopa</TI>
<SO>Clinical Physiology</SO>
<YR>1984</YR>
<VL>4</VL>
<NO>4</NO>
<PG>275-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novo-1985" MODIFIED="2013-09-05 15:16:32 +0100" MODIFIED_BY="Dolores Matthews" NAME="Novo 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-09-05 15:16:32 +0100" MODIFIED_BY="Dolores Matthews" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novo S, Pinto A, Galati D, Giannola A, Forte G, Strano A</AU>
<TI>Effects of chronic administration of selective beta blockers on peripheral circulation of lower limbs in patients with essential hypertension</TI>
<SO>International Angiology</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>2</NO>
<PG>229-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Novo-1986" MODIFIED="2013-08-14 12:25:30 +0100" MODIFIED_BY="Sharath C V  Paravastu" NAME="Novo 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-08-14 12:25:30 +0100" MODIFIED_BY="Sharath C V  Paravastu" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Novo S, Alaimo G, Abrignani MG, Giordano U, Avellone G, Pinto A, et al</AU>
<TI>Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arterioscleorosis obliterans of the lower limb</TI>
<SO>International Journal of Clinical and Pharmacology Research</SO>
<YR>1986</YR>
<VL>6</VL>
<NO>3</NO>
<PG>199-211</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reichert-1975" MODIFIED="2008-07-09 08:51:25 +0100" MODIFIED_BY="[Empty name]" NAME="Reichert 1975" YEAR="1975">
<REFERENCE MODIFIED="2008-07-09 08:51:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reichert N, Shibolet S, Adar R, Gafni J</AU>
<TI>Controlled trial of propranolol in intermittent claudication</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1975</YR>
<VL>17</VL>
<NO>5</NO>
<PG>612-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schweizer-1996" MODIFIED="2013-08-14 14:50:03 +0100" MODIFIED_BY="Sharath C V  Paravastu" NAME="Schweizer 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-08-14 14:50:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schweizer J, Kaulen R, Altmann E, Nierade A, Nanning T</AU>
<TI>Are beta-blockers generally contraindicated in patients with peripheral arterial occlusive disease?</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>3</NO>
<PG>193-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-14 14:28:47 +0100" MODIFIED_BY="Sharath C V  Paravastu" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schweizer J, Kaulen R, Nierade A, Altmann E.</AU>
<TI>Beta- blockers and nitrates in patients with peripheral arterial occlusive disease: long-term findings.</TI>
<SO>VASA. Zeitschrift für Gefässkrankheiten</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>1</NO>
<PG>43-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skotnicki-1984" NAME="Skotnicki 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skotnicki SH, van Gaal G, Wijn PF</AU>
<TI>The effectiveness of Isoxsuprine in patients with intermittent claudication</TI>
<SO>Angiology</SO>
<YR>1984</YR>
<VL>35</VL>
<NO>11</NO>
<PG>685-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1982" NAME="Smith 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith RS, Warren DJ</AU>
<TI>Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication</TI>
<SO>Journal of Cardiovascular Pharmacology</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>1</NO>
<PG>2-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strandness-1970" MODIFIED="2008-07-09 08:53:59 +0100" MODIFIED_BY="[Empty name]" NAME="Strandness 1970" YEAR="1970">
<REFERENCE MODIFIED="2008-07-09 08:53:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strandness D Jr</AU>
<TI>Ineffectiveness of isoxsuprine on intermittent claudication</TI>
<SO>JAMA</SO>
<YR>1970</YR>
<VL>213</VL>
<NO>1</NO>
<PG>86-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svendsen-1985" MODIFIED="2013-09-05 15:16:47 +0100" MODIFIED_BY="Sharath C V  Paravastu" NAME="Svendsen 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-09-05 15:16:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svendsen TL, Jelnes R, Tonnesen KH</AU>
<TI>Is adrenergic beta receptor blockade contraindicated in patients with intermittent claudication</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1985</YR>
<VL>693</VL>
<PG>129-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-14 14:29:00 +0100" MODIFIED_BY="Sharath C V  Paravastu" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svendsen TL, Jelnes R, Tonnesen KH</AU>
<TI>The effects of acebutolol and metoprolol on walking distances and distal blood pressure in hypertensive patients with intermittent claudication</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1986</YR>
<VL>219</VL>
<NO>2</NO>
<PG>161-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-de-Ven-1994" MODIFIED="2013-09-05 15:17:01 +0100" MODIFIED_BY="[Empty name]" NAME="van de Ven 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-09-05 15:17:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van de Ven LL, van Leeuwen JT, Smit AJ</AU>
<TI>The influence of chronic treatment with beta blockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial</TI>
<SO>VASA. Zeitschrift für Gefässkrankheiten</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>4</NO>
<PG>357-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-09-05 15:19:53 +0100" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2013-09-05 15:19:53 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-ACCF_x002f_AHA-2012" MODIFIED="2013-09-05 15:17:28 +0100" MODIFIED_BY="Sharath C V  Paravastu" NAME="ACCF/AHA 2012" TYPE="OTHER">
<AU>Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al</AU>
<TI>2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non&#8211;ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</TI>
<SO>Journal of American College of Cardiology</SO>
<YR>2013</YR>
<VL>61</VL>
<NO>23</NO>
<PG>e179 &#8211;347</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bangalore-2007" MODIFIED="2010-02-16 15:39:42 +0000" MODIFIED_BY="Heather Maxwell" NAME="Bangalore 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bangalore S, Parkar S, Grossman E, Messerli FH</AU>
<TI>A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus</TI>
<SO>American Journal of Cardiology</SO>
<YR>2007</YR>
<VL>100</VL>
<NO>8</NO>
<PG>1254-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-BNF-2013" MODIFIED="2013-08-07 08:52:02 +0100" MODIFIED_BY="[Empty name]" NAME="BNF 2013" TYPE="BOOK">
<AU>Joint Formulary Committee</AU>
<SO>British National Formulary</SO>
<YR>2013</YR>
<VL>65</VL>
<PB>British Medical Association and Royal Pharmaceutical Society of Great Britain</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2010" MODIFIED="2013-08-05 08:40:18 +0100" MODIFIED_BY="Heather Maxwell" NAME="Chen 2010" TYPE="COCHRANE_REVIEW">
<AU>Chen JMH, Heran BS, Perez MI, Wright JM</AU>
<TI>Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-08-05 08:36:29 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2013-08-05 08:36:29 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD007185.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Criqui-1985" MODIFIED="2010-02-16 14:54:20 +0000" MODIFIED_BY="Heather Maxwell" NAME="Criqui 1985" TYPE="JOURNAL_ARTICLE">
<AU>Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D</AU>
<TI>The prevalence of peripheral arterial disease in a defined population</TI>
<SO>Circulation</SO>
<YR>1985</YR>
<VL>71</VL>
<NO>3</NO>
<PG>510-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-George-1974" MODIFIED="2008-07-09 08:54:53 +0100" MODIFIED_BY="[Empty name]" NAME="George 1974" TYPE="JOURNAL_ARTICLE">
<AU>George CF</AU>
<TI>Beta-receptor blocking agents</TI>
<SO>Prescribers Journal</SO>
<YR>1974</YR>
<VL>14</VL>
<PG>93-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hiatt-2001" NAME="Hiatt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hiatt WR</AU>
<TI>Medical treatment of peripheral arterial disease and claudication</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>21</NO>
<PG>1608-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-09-05 15:17:46 +0100" MODIFIED_BY="Sharath C V  Paravastu" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>www.cochrane-handbook.org</SO>
<PB>The Cochrane Collaboration</PB>
<MD>www.cochrane-handbook.org</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughson-1978" MODIFIED="2013-09-05 15:18:25 +0100" MODIFIED_BY="Heather Maxwell" NAME="Hughson 1978" TYPE="JOURNAL_ARTICLE">
<AU>Hughson WG, Mann JI, Garrod A</AU>
<TI>Intermittent claudication: prevalence and risk factors</TI>
<SO>British Medical Journal</SO>
<YR>1978</YR>
<VL>1</VL>
<NO>6124</NO>
<PG>1379-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" MODIFIED="2010-02-16 14:54:29 +0000" MODIFIED_BY="Heather Maxwell" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomised clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Javed-2009" MODIFIED="2010-02-16 15:20:13 +0000" MODIFIED_BY="Heather Maxwell" NAME="Javed 2009" TYPE="JOURNAL_ARTICLE">
<AU>Javed U, Deedwania PC</AU>
<TI>Beta-adrenergic blockers for chronic heart failure</TI>
<SO>Cardiology in Review</SO>
<YR>2009</YR>
<VL>17</VL>
<NO>6</NO>
<PG>287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kannel-1985" MODIFIED="2010-02-16 14:54:33 +0000" MODIFIED_BY="Heather Maxwell" NAME="Kannel 1985" TYPE="JOURNAL_ARTICLE">
<AU>Kannel WB, McGee DL</AU>
<TI>Update on some epidemiologic features of intermittent claudication: the Framingham Study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1985</YR>
<VL>33</VL>
<NO>1</NO>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lassila-1986" MODIFIED="2013-09-05 15:19:29 +0100" MODIFIED_BY="Heather Maxwell" NAME="Lassila 1986" TYPE="JOURNAL_ARTICLE">
<AU>Lassila R, Lepantalo M, Lindfors O</AU>
<TI>Peripheral arterial disease&#65293;natural outcome</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1986</YR>
<VL>220</VL>
<NO>4</NO>
<PG>295-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lavie-2009" MODIFIED="2010-02-16 15:48:56 +0000" MODIFIED_BY="Heather Maxwell" NAME="Lavie 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lavie CJ, Messerli FH, Milani RV</AU>
<TI>Beta-blockers as first-line antihypertensive therapy: the crumbling continues</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2009</YR>
<VL>54</VL>
<NO>13</NO>
<PG>1162-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindholm-2005" MODIFIED="2010-02-16 15:04:46 +0000" MODIFIED_BY="Heather Maxwell" NAME="Lindholm 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lindholm LH, Carlberg B, Samuelsson O</AU>
<TI>Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<NO>9496</NO>
<PG>1545-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MIAMI-trial" NAME="MIAMI trial" TYPE="JOURNAL_ARTICLE">
<AU>MIAMI Trial Researchers</AU>
<TI>Metoprolol in acute myocardial infarction. Other clinical findings and tolerability. The MIAMI Trial Research Group</TI>
<SO>American Journal of Cardiology</SO>
<YR>1985</YR>
<VL>56</VL>
<NO>14</NO>
<PG>G39-G46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miyajima-2004" MODIFIED="2013-08-02 15:06:51 +0100" MODIFIED_BY="Sharath C V  Paravastu" NAME="Miyajima 2004" TYPE="JOURNAL_ARTICLE">
<AU>Miyajima R, Sano K, Yoshida H</AU>
<TI>Beta-adrenergic blocking agents and intermittent claudication: systematic review</TI>
<SO>Yakugaku Zasshi</SO>
<YR>2004</YR>
<VL>124</VL>
<NO>11</NO>
<PG>825-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2010" MODIFIED="2013-09-05 15:19:53 +0100" MODIFIED_BY="Heather Maxwell" NAME="NICE 2010" TYPE="OTHER">
<AU>NICE</AU>
<TI>Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. Clinical guidelines CG108: August 2010 Issue</TI>
<SO>www.nice.org.uk (accessed 7 August 2013)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2010-02-16 14:54:46 +0000" MODIFIED_BY="Heather Maxwell" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiysonge-2007" MODIFIED="2013-08-05 08:39:39 +0100" MODIFIED_BY="Heather Maxwell" NAME="Wiysonge 2007" TYPE="COCHRANE_REVIEW">
<AU>Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al</AU>
<TI>Beta-blockers for hypertension</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-08-05 08:39:39 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2013-08-05 08:39:39 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD002003.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wright-2009" MODIFIED="2013-08-05 08:39:20 +0100" MODIFIED_BY="Heather Maxwell" NAME="Wright 2009" TYPE="COCHRANE_REVIEW">
<AU>Wright JM, Musini VM</AU>
<TI>First-line drugs for hypertension</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-08-05 08:37:26 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2013-08-05 08:37:26 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD001841.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-08-05 08:41:16 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Paravastu-2008" MODIFIED="2013-08-05 08:41:16 +0100" MODIFIED_BY="[Empty name]" NAME="Paravastu 2008" TYPE="COCHRANE_REVIEW">
<AU>Paravastu SCV, Mendonca D, Da Silva A</AU>
<TI>Beta blockers for peripheral arterial disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-08-02 14:34:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-08-02 14:34:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005508.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-09-11 11:38:02 +0100" MODIFIED_BY="Heather  Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-09-05 15:09:37 +0100" MODIFIED_BY="Heather  Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-09-05 15:01:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clement-1980">
<CHAR_METHODS MODIFIED="2013-09-05 15:01:25 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled, cross-over trial<BR/>Method of randomisation: not stated<BR/>Concealment of allocation: not stated<BR/>Exclusions post-randomisation: none<BR/>Losses to follow-up: none<BR/>Intention-to-treat analysis: yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-05 15:01:31 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Belgium<BR/>Setting: hospital<BR/>Number: 10<BR/>Age: 62 ± 2 years (mean ± SEM)<BR/>Sex: male<BR/>Inclusion criteria: chronic intermittent claudication<BR/>Exclusion criteria: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-05 15:01:42 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: propranolol (80 mg bid); metoprolol (100 mg bid)<BR/>Control: placebo<BR/>Duration: All participants entered a run-in, wash-out period of 4 weeks, followed by propranolol, metoprolol or placebo, each for 2 months<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-05 15:01:44 +0100" MODIFIED_BY="Dolores Matthews">
<P>Claudication time and maximum walking time</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-05 15:06:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hiatt-1985">
<CHAR_METHODS MODIFIED="2013-09-05 15:01:57 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled, cross-over trial<BR/>Method of randomisation: not stated<BR/>Concealment of allocation: not stated<BR/>Exclusions post-randomisation: none<BR/>Losses to follow-up: none<BR/>Intention-to-treat analysis: yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-05 15:06:15 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Setting: hospital<BR/>Number: 19<BR/>Age: sequence 1, 57 ± 3 years (mean ± SEM); sequence 2, 58 ± 3 years (mean ± SEM)<BR/>Sex: male 16; female 3<BR/>Inclusion criteria: diagnosis of chronic stable intermittent claudication confirmed by previous non-invasive testing<BR/>Exclusion criteria: ischaemic pain at rest (due to inability to exercise); patients with angina, arrhythmias or congestive heart failure; contraindications to the use of &#946;-adrenergic blockers<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-05 15:06:36 +0100" MODIFIED_BY="Dolores Matthews">
<P>Treatment: propranolol (40 mg tid); metoprolol (50 mg tid)<BR/>Control: placebo<BR/>Duration: All participants entered a single-blind, placebo run-in phase period of 3 weeks followed by propranolol or metoprolol. After taking a drug for 2 weeks, participants received 2 weeks of placebo and then crossed over to the other drug</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-07 14:06:12 +0100" MODIFIED_BY="[Empty name]">
<P>Calf blood flow and vascular resistance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-05 15:06:39 +0100" MODIFIED_BY="[Empty name]">
<P>Sequence 1: metoprolol before propranolol<BR/>Sequence 2: propranolol before metoprolol<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-05 15:07:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lepantalo-1984a">
<CHAR_METHODS MODIFIED="2013-09-05 15:06:52 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled, cross-over trial<BR/>Method of randomisation: not stated<BR/>Concealment of allocation: not stated<BR/>Exclusions post-randomisation: unsure, "17 patients recruited, 14 completed study"<BR/>Losses to follow-up: unsure<BR/>Intention-to-treat analysis: unsure<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-05 15:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Finland<BR/>Setting: hospital<BR/>Number: 14<BR/>Age: 41 to 73 years<BR/>Sex: male 9; female 5<BR/>Inclusion criteria: confirmed diagnosis of intermittent claudication (pathological ankle/arm systolic blood pressure ratio)<BR/>Exclusion criteria: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-05 15:07:15 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: metoprolol (100 to 200 mg/d); methyldopa (500 to 1000 mg/d)<BR/>Control: placebo<BR/>Duration: 4 × 3-week periods (1 run-in period with placebo and 3 treatment periods with metoprolol, methyldopa or placebo<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-05 15:07:16 +0100" MODIFIED_BY="Dolores Matthews">
<P>Vascular resistance and calf blood flow</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-05 15:07:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lepantalo-1985">
<CHAR_METHODS MODIFIED="2013-09-05 15:07:25 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled, cross-over trial<BR/>Method of randomisation: not stated<BR/>Concealment of allocation: not stated<BR/>Exclusions post-randomisation: 2 excluded after run-in period<BR/>Losses to follow-up: unsure<BR/>Intention-to-treat analysis: unsure</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-05 15:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Finland<BR/>Setting: hospital<BR/>Number: 7<BR/>Age: average age 60 (range 49 to 70) years<BR/>Sex: male<BR/>Inclusion criteria: intermittent claudication<BR/>Exclusion criteria: not stated<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-05 15:07:47 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: propranolol (80 mg bid); pindolol (5 mg bid); labetalol (200 mg bid); labetalol (400 mg bid)<BR/>Control: placebo (bid)<BR/>Duration: 7 × 10-day treatment periods; a run-in period with placebo; 5 treatment periods with propranolol (80 mg bid); pindolol (5 mg bid); labetalol (200 mg bid); labetalol (400 mg bid) and placebo (bid)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-05 15:07:48 +0100" MODIFIED_BY="[Empty name]">
<P>Calf blood flow and vascular resistance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-09-05 15:07:50 +0100" MODIFIED_BY="[Empty name]">
<P>"Only 7 completed the trial"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-05 15:08:39 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Roberts-1987">
<CHAR_METHODS MODIFIED="2013-09-05 15:08:19 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, placebo-controlled, cross-over trial with single-blind and double-blind periods<BR/>Method of randomisation: randomised codes<BR/>Concealment of allocation: tablets dispensed monthly by hospital pharmacy staff; independent observer aware of codes assessed participants' symptoms at each visit<BR/>Exclusions post-randomisation: 3 withdrawn because of development of other cardiovascular diseases<BR/>Losses to follow-up: 3<BR/>Intention-to-treat analysis: unsure<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-05 15:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>Country: UK<BR/>Setting: hospital<BR/>Number: 23 recruited, 20 completed the study<BR/>Age: mean 58 years (SEM 2)<BR/>Sex: 17 male; 6 female<BR/>Inclusion criteria: intermittent claudication confirmed by clinical observation and aortofemoral angiography<BR/>Exclusion criteria: ischaemic pain at rest; diabetes mellitus; angina or congestive heart failure; contraindications to the use of &#946;-adrenergic blockers or ACE inhibitors (e.g. renal failure)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-05 15:08:36 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Treatment: captopril (25 mg bid); labetalol (200 mg bid); pindolol (10 mg bid); atenolol (100 mg od)<BR/>Control: placebo<BR/>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-05 15:08:39 +0100" MODIFIED_BY="Dolores Matthews">
<P>Calf blood flow, claudication distance and maximum walking distance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-07 14:08:58 +0100" MODIFIED_BY="Sharath C V  Paravastu"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-05 15:09:30 +0100" MODIFIED_BY="Heather  Maxwell" STUDY_ID="STD-Solomon-1991">
<CHAR_METHODS MODIFIED="2013-09-05 15:09:11 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised, double-blind, placebo-controlled, cross-over trial<BR/>Method of randomisation: computer<BR/>Concealment of allocation: not stated<BR/>Exclusions post-randomisation: none<BR/>Losses to follow-up: none<BR/>Intention-to-treat analysis: yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-09-05 15:09:26 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Country: UK<BR/>Setting: hospital<BR/>Number: 49<BR/>Age: 39 to 70 years<BR/>Sex: 40 male; 9 female<BR/>Inclusion criteria: stable intermittent claudication of at least 6 months' duration<BR/>Exclusion criteria: rest pain; angina, which limited exercise before claudication; recent myocardial infarction; insulin-dependent diabetes; serum creatinine concentrations &gt; 200 µmol/L; contraindications to the use of &#946;-adrenergic blockers; co-prescription of peripheral vasodilators, ACE inhibitors or calcium antagonists</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-05 15:09:29 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment: atenolol (50 mg bid); slow-release nifedipine (20 mg bid); atenolol (50 mg) + slow-release nifedipine (20 mg) bid<BR/>Control: placebo<BR/>Duration: each treatment given for 4 weeks with no wash-out interval between treatments</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-09-05 15:09:30 +0100" MODIFIED_BY="Dolores Matthews">
<P>Claudication and walking distances, skin temperature</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACE: angiotensin-converting enzyme.<BR/>bid: twice daily.<BR/>od: once daily.<BR/>SEM: standard error of the mean.<BR/>tid: three times daily.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-09-11 11:38:02 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:09:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aarts-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:09:47 +0100" MODIFIED_BY="[Empty name]">
<P>In this randomised, double-blind, placebo-controlled trial, the in vivo effect of isoxsuprine on deformability of red blood cells was studied. The study was excluded, as no data were available regarding the primary or secondary outcomes considered for this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:10:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bostrom-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:10:01 +0100" MODIFIED_BY="[Empty name]">
<P>The short-term effects of beta blockers with and without intrinsic sympathomimetic effects on leg blood flow and walking distance were compared in participants with intermittent claudication and hypertension. The study was excluded as it was a comparative study between atenolol (100 mg od) and pindolol (10 mg od). Placebo was not used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:10:12 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Brown-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:10:12 +0100" MODIFIED_BY="Dolores Matthews">
<P>This randomised, double-blind trial assessed single and combination therapy anti-hypertensives in achieving target blood pressure. This study was excluded, as the drug used in the study (nifedipine) is a calcium channel blocker</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:10:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diehm-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>In this randomised, double-blind, parallel-group study, the effects of tertatolol (5 mg od) on lipid profile, walking tolerance and blood pressure control in participants with peripheral arterial disease were compared with those of metoprolol (200 mg od). This study was excluded, as it was a comparative study and placebo was not used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-07-04 13:44:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diehm-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-07-04 13:44:38 +0100" MODIFIED_BY="[Empty name]">
<P>Compared beta blocker with a diuretic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:10:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ehrly-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:10:28 +0100" MODIFIED_BY="[Empty name]">
<P>Compared beta blocker with another beta blocker but not with placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:10:35 +0100" MODIFIED_BY="Sharath C V  Paravastu" STUDY_ID="STD-Espinola_x002d_Klein-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:10:35 +0100" MODIFIED_BY="Sharath C V  Paravastu">
<P>This RCT compared nebivolol with metoprolol in participants with arterial occlusive disease; however, placebo was not used, hence excluded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:10:53 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Forbes-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:10:53 +0100" MODIFIED_BY="Dolores Matthews">
<P>In this randomised, double-blind, cross-over trial, the safety and pharmacodynamic compatibility of clopidogrel were assessed in participants taking beta blockers and calcium channel blockers. The study was excluded, as no data regarding the primary or secondary outcomes considered for this review were provided</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:11:12 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Iarussi-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:11:12 +0100" MODIFIED_BY="Dolores Matthews">
<P>The effects of delayed action isoxsuprine on peripheral circulation were evaluated in this trial. It was excluded, as no reference was made to participants with peripheral vascular disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:11:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karnik-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:11:23 +0100" MODIFIED_BY="[Empty name]">
<P>The effects on peripheral blood flow of beta blockers with and without intrinsic sympathomimetic activities were assessed. The study was excluded as it was a comparator study between celiprolol (200 mg od) and metoprolol (200 mg od). Placebo was not used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:11:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klieber-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:11:37 +0100" MODIFIED_BY="[Empty name]">
<P>The effects of celiprolol (300 mg/d) and propranolol (120 mg/d) on peripheral blood flow in participants with PAD were studied in this randomised, double-blind trial. This study was excluded as it was a comparative study, and placebo was not used<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:11:49 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Konecny-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:11:49 +0100" MODIFIED_BY="Dolores Matthews">
<P>In this trial, the acute effect of IV celiprolol on resting calf blood flow in healthy participants and participants with peripheral arterial disease was evaluated. The trial was excluded, as data were insufficient.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-11 11:37:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lepantalo-1984b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-11 11:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>This randomised, double-blind, placebo-controlled trial considered the effects of a 3-week course of metoprolol (100 to 200 mg/d) and methyldopa (500 to 1000 mg/d) on walking capacity in participants with intermittent claudication. The trial was excluded, as insufficient data were available. The values were given as multiples of baseline. However, the baseline values were not provided.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:12:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Novo-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:12:28 +0100" MODIFIED_BY="[Empty name]">
<P>This study looked at chronic effects of beta blockers in lower limbs in participants with hypertension. Some of the participants for whom results were collated had peripheral vascular disease. However, this was not a randomised study of participants with peripheral vascular disease, hence it was excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:12:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Novo-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:12:46 +0100" MODIFIED_BY="[Empty name]">
<P>This study evaluated the effects of ketanserin on blood pressure, peripheral circulation, and haemocoagulative parameters in participants with or without arteriosclerosis obliterans. The study was excluded as ketanserin is an anti-serotoninergic drug and is not a beta blocker.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:13:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reichert-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:13:09 +0100" MODIFIED_BY="[Empty name]">
<P>In this randomised, double-blind trial, the effects of propranolol compared with placebo on claudication pain were tested. The study was excluded, as it had a mixed cohort of participants, and the dosages administered to different participants were different.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:13:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schweizer-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>The effects of celiprolol (200 mg od), atenolol (50 mg od) and isosorbide (40 mg bid) on peripheral blood flow in participants with PAD were evaluated in this randomised, double-blind, placebo-controlled trial. This trial, published in German, was excluded, as the results were presented in graphs only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:13:51 +0100" MODIFIED_BY="Dolores Matthews" STUDY_ID="STD-Skotnicki-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:13:51 +0100" MODIFIED_BY="Dolores Matthews">
<P>This randomised, double-blind, placebo-controlled trial evaluated the effects of isoxsuprine on pain-free walking distance in participants with intermittent claudication. The data were presented in graphs, hence excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-11 11:37:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-11 11:37:59 +0100" MODIFIED_BY="[Empty name]">
<P>This trial evaluated the effects of beta blockers on calf blood flow in participants with peripheral vascular disease. The results were presented in graphs only and hence were excluded.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:14:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Strandness-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:14:03 +0100" MODIFIED_BY="[Empty name]">
<P>In this randomised trial, the effects of isoxsuprine (200 mg tid) and placebo on post-exercise blood pressure were assessed. The study was excluded, as not enough data were available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-05 15:14:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svendsen-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-05 15:14:19 +0100" MODIFIED_BY="[Empty name]">
<P>In this randomised, cross-over trial, the effects of acebutolol (400 mg od) and metoprolol (100 mg bid) on blood pressure and walking distances in participants with essential hypertension and chronic intermittent claudication were compared. The trial was excluded, as it was a comparator study (placebo was not used).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-09-11 11:38:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-de-Ven-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-09-11 11:38:02 +0100" MODIFIED_BY="[Empty name]">
<P>Compared beta blocker with ACE inhibitor.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>bid: two times daily<BR/>IV: intravenous<BR/>od: once daily<BR/>PAD: peripheral arterial disease<BR/>tid: three times daily</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-09-05 15:09:32 +0100" MODIFIED_BY="Sharath C V  Paravastu">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-08-14 15:47:09 +0100" MODIFIED_BY="Sharath C V  Paravastu" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:09 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Clement-1980">
<DESCRIPTION>
<P>Randomisation method not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 12:38:46 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Hiatt-1985">
<DESCRIPTION>
<P>Method of randomisation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 12:39:58 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Lepantalo-1984a">
<DESCRIPTION>
<P>Method of randomisation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 12:42:04 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Lepantalo-1985">
<DESCRIPTION>
<P>Method of randomisation not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-02 13:39:56 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1987">
<DESCRIPTION>
<P>Randomisation codes used but method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 15:05:31 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Solomon-1991">
<DESCRIPTION>
<P>Computerised randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-08-14 15:47:09 +0100" MODIFIED_BY="Sharath C V  Paravastu" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:09 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Clement-1980">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 12:37:58 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Hiatt-1985">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 12:39:58 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Lepantalo-1984a">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 12:42:04 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Lepantalo-1985">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 14:09:32 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1987">
<DESCRIPTION>
<P>Tablets dispensed monthly by hospital pharmacy staff, no further details available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1991">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-09-05 15:08:45 +0100" MODIFIED_BY="Sharath C V  Paravastu" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-14 15:47:09 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Clement-1980">
<DESCRIPTION>
<P>Reports 'double-blind', no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Hiatt-1985">
<DESCRIPTION>
<P>Reports 'double-blind', no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Lepantalo-1984a">
<DESCRIPTION>
<P>Reports 'double-blind', no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Lepantalo-1985">
<DESCRIPTION>
<P>Reports 'double-blind', no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-09-05 15:08:45 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="NO" STUDY_ID="STD-Roberts-1987">
<DESCRIPTION>
<P>Independent observer aware of codes assessed participants' symptoms at each visit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-15 09:54:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1991">
<DESCRIPTION>
<P>Reports 'double-blind', no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-07-02 14:09:45 +0100" MODIFIED_BY="Sharath C V  Paravastu" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-09-05 15:08:54 +0100" MODIFIED_BY="Sharath C V  Paravastu" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-14 15:47:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Clement-1980">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hiatt-1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Lepantalo-1984a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Lepantalo-1985">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-09-05 15:08:54 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="NO" STUDY_ID="STD-Roberts-1987">
<DESCRIPTION>
<P>Independent observer aware of codes assessed participants' symptoms at each visit</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Solomon-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-09-05 15:09:32 +0100" MODIFIED_BY="Sharath C V  Paravastu" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-05 15:01:47 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Clement-1980">
<DESCRIPTION>
<P>Analysis was intention-to-treat, no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-05 15:06:42 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Hiatt-1985">
<DESCRIPTION>
<P>Analysis was intention-to-treat, no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-05 15:07:18 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Lepantalo-1984a">
<DESCRIPTION>
<P>Unclear about losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-05 15:07:55 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Lepantalo-1985">
<DESCRIPTION>
<P>Unclear details on whether analysis was intention-to-treat</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-05 15:09:01 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Roberts-1987">
<DESCRIPTION>
<P>Unclear whether analysis was intention-to-treat. 3 participants were withdrawn because of development of other cardiovascular diseases. 3 participants were lost to follow-up<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-09-05 15:09:32 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Solomon-1991">
<DESCRIPTION>
<P>Analysis was intention-to-treat, no losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-08-14 15:47:09 +0100" MODIFIED_BY="Sharath C V  Paravastu" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:09 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Clement-1980">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Hiatt-1985">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Lepantalo-1984a">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Lepantalo-1985">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 14:09:32 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Roberts-1987">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1991">
<DESCRIPTION>
<P>No evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-09-05 15:08:01 +0100" MODIFIED_BY="Sharath C V  Paravastu" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-05 15:01:48 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="UNKNOWN" STUDY_ID="STD-Clement-1980">
<DESCRIPTION>
<P>Details on cross-over inadequately provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Hiatt-1985">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Lepantalo-1984a">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-05 15:08:01 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="NO" STUDY_ID="STD-Lepantalo-1985">
<DESCRIPTION>
<P>Exclusion criteria unclear; losses to follow-up unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 14:09:33 +0100" MODIFIED_BY="Sharath C V  Paravastu" RESULT="YES" STUDY_ID="STD-Roberts-1987">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 15:47:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Solomon-1991">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2013-09-05 15:09:33 +0100" MODIFIED_BY="Sharath C V  Paravastu">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-08-07 08:26:01 +0100" MODIFIED_BY="Karen Welch" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAALPCAYAAAD2NqGnAABl7ElEQVR42uydD0Rf7f//v8xtMjMj
c8tkIkmSRHLLJCMzc7vNmMzM7XYzyWRyM0mSRJJJMia5JRMzk5mMydwyE5NkZkYmSWYkM8lcP8/r
9zlv1/vsfc51zrva3tXjwVHv9znnOtd1zuv1up7v68+5/s84/N///R8bG1vCrdDgmWB/2B/bUbU/
2IXvuk4MAOkqPvICPHPsD/uDAy8EeaAABzcY4r/YH/YHPHvYxXPkQQIc1GCI/wL2B4hBQAgCUBED
9of9ATYACEEAKmLA/rA/wAYAIQhARQzYH/YH2AAgBAGoiAH7w/4AGwCEIAAVMWB/2B9gA/DjhODS
0hJ3GgiEBGHA/goe6itsACHoMDU1Zc6dO2eOHz9u6uvrzeLiYl4X0fl7aWz7ZXh7le5u09nP8w+S
0x6UvBZyRfz161dTXl7+3ffr6+vmjz/+sL5ZVFRkrl69ajY2NhKfL/755x9z8uTJzPlKk0oM+0tq
P0n272feouqUcH31I+/vQbRHhOAhFoKvX782DQ0NZmVlxXz79s1MTk6aysrKn2YoR0nA/Ozz4XBU
xDs7O+bKlSs5j2lubjYPHz60vq1N/1+4cCHx+YODg2ZkZCRzfl9fn2lqauLZYX+J7CfJ/h8pBA+K
sMb+4IcKwdbWVhvsk/L06VPzyy+/mGPHjpnq6mozNzeXMZLw+oS5rul+p4qlra3NtjaUlJTYlsm4
FsHe3l5z6tQpc+LECdPR0ZEoX0l+IY6Pj5vS0lJ7rtJ49uxZZv/29ra5ceOGbQ2pqKgw8/Pz3l+a
+ZTVV74k5+dbxlznTkxMmOLiYpuX9vZ2+4ve3f/q1Stz5swZU1dXF5v/ra0tc/bs2azzg/uq55Tr
3qkFSmnonkt0rK6uJr7PaezgsFTEukcfP37MeYzuhe+7uPPLysrMly9fvGnmYxtJfCyJPYSv5/OV
/bSRoygE4+wnyX6XDx8+mMuXL9tnrWcke3j8+HHiOJi0TklSX/nsLi6m+sqBEISCEoIy5DRjJVyD
n52dtRVFlKH4Ku3h4WHT399vnVfdVY2NjZHiamxszDqejtUvTDn4wMBAonz5RJIcNnBypeFWdN3d
3WZ6etr+PzMzk9VamkYI+srqK5/v/N2UMde5tbW19nhdT5X47du3s/ZLHGrf2tqaN/+3bt0yQ0ND
WddQeZRuOK86zm2BUroSCUnvcxo7OCwV8fPnzyOPCVoEA2TL58+fT3y+y+bmpn1m+vEYl880tuHz
sST2EL6ez1f200aOohD02U9S+xI1NTW2Vyp43nr2EvlJ42CaOiWuvkpid3Ex1VcOhCAUlBCU8SoY
6hdLMAbo8+fPkQnJmIOg7TMUX6WtX/BqDQhYWFiIdFQJEzlUuLUiSb58Isn9pRfer0opfN18hKCv
rL7y+c7fTRlzneu2yqhFSK16cenF5f/t27f2/GC//mpMapCGm5eqqqqscup/tUwmvc9p7OCwVMRx
x+jenz59OtPyof/1XdprXLt2zbaOaHvz5k1sHtLYhs/HkthD+Ho+X9lPGzmKQjDpMfnmXy1uSZ9t
mjolrr7Kx+585XPLgRCEghKC+l4tNvq1H/zyifvFL9EYtBj19PTsSgiGW6V0/ShH1bHh5nzXseLy
tRsB52s526uy+srnO383ecu1L1wxu9eP6oKMy79aodQqJPRLWb+mc6XnnpP02u53aezgKFTEus9q
3QhaJjQMROO18r2GusuCLv2kaaS17ajKM40txvnKftoIQnD3+VdXv1qJVQ9JkKWNo0nrlLj6ardx
yFcOhCAUlBDUWAr3l48cxzf7VwauLpyWlhbT2dm5Z0IwzlFzOWbSfBWiEExbPt/5ey0E0wZBX/71
XNTqLCQkgu6i3dhEXABOYgdHoSKWL7uiXv+r5T/fa6hrN6lP7Ma2d2MPSXxlv2wEIbi7NDQ2WS3E
Dx48sDFC3f1p4kMae4mrr3Ybh3zlQAhCQQnBixcvfvcLKqqiCKPXzCR1LKGZye53mq3sitDl5eXI
9CQe1GqZT75249B65UE+XcNpy+orn+/8vRaC7iuENFRAPxjizk3yfDQeVWN41C0clRelE+6ScX+Y
+O5zGjs4ChVx2Jdly+reTXq+ulHd182Eu8iSpOGzjTgfS2sPaX1lr20EIbi7NBRnXFtJG0fT1Clx
9VU+dud+5ysHQhAKSghqrIy2oOvo3r179l2CUehXjmbdifAAWVU6GjcROJA7KFuzxtRN5eZDXYR6
HUUwsFcD26OcRd1bwSBgbfrsvsYiLl+7EUlq2ldXknjx4kXkZJHdltVXPt/5ey0EdW1dR9e7e/du
VndirnN9+ReaIKCZfO5EgVzPWTYYpDM6Opr1/jHffU5jB0ehItZECrVKqCVP91NCXLMqk56vrmB1
nwbPQ7agLU0efLYR52M+e8h1PZ+v7KeNIAR3l4Z+LAazayXiVBeliaNp6pRwfZUmDvliqq8cCEEo
KCEoZPD65a9fPKpY3717F3msulQ03iGYMh8E1KCiVxrBL6cgyOpYOZGODedDY5bUwqBXS2h8Ypyz
dHV12V9aQT6DWYK+fO1GJOm1J5pAozSVvgYf5zput2X1lS/J+XspBBXEfv31V2sXd+7cyZpAFHWu
L/+fPn2y+8IvNI56bYM2zdR7//594vucxg6OQkUs+5UYDPxSIjD8Kp+48yUgg/P1PPRs8slnnG3E
+ZjPHqKuF+cr+2kjCMHdpfHy5Us7kUjPRYJdjRRp42jSOiVcX6WJQ76Y6isHQhAKTggC4PAHvyIG
7A/7A2wAEIKAw1MRA/aH/QE2AAhByI+9WDOaQEgQBuwPsD9ACAIQCAnCgP0B9gcIQQACIUEYsD/A
/gAhCEAgJAgD9gfYHyAEAQiEBGHA/gD7A4QgAIGQIAzYH2B/gBAEIBAWWhBeWloqiOdQKPnA/uAo
2TE2gBDEkCgvTlSAFfFerOaQlPBrhdy0tTqHVlGora3dk+vGnR+Xj8NsKwjB/c/vUfQn6jOEIAAc
4op4L/Mcl5a7BvR+Xyu8DyGIEPxR+T2M/oQQPOJC8OzZs9+tO6oFuKurqzOfe3t77ZqNWm+xo6Pj
O8PQup1aj7auri7rl4zW8VQ6c3NzkYYUrOWoxb+1CL0WAHePHR8ft4t3B2uC+hzDl144r7kMPdcx
ue7B1taW9/6Fyxt1L8+dO2fX4RUrKyv2vNevX9vP6+vrdj8gBH3ff/v2za4lrDV9S0pKzNTUVGIb
9Pmc9rmbe+24fUmumyTfbh5zXUvrpUfFiii/9sUL3zNQmZTn06dPm5GRke/Wko3L02Gyv6Qx042R
WrtX972iosLMz8/vKo777CeuTjrq/oQQRAiaW7dumaGhoazvhoeHrZEJLdgtQ5ZhafF5GZQW6nYN
QwvSa3+wiLxr7LOzs3bh7VyGpOsqeOpcbbqWgoN7rBanD4KA0lTaUSRJL5zXXIYePibuHvjun1ve
uHSuX79uHj16ZP9/+PCh7TLQ8cFntxyAEIz6XrbX399vbWxjY8M0NjYmtsEkPhfXEhe3z3ddX76T
tAheunQpNt9hv04SL+Kuq/J0dnZm8vzbb799dz/i8nSY7C9NzBTd3d1menra/j8zM2MqKyt3Fcd9
9hNXJ+FPCMEjLwTfvn1rW7VkMMEvCbU+BYar8QnBvoCwsHN/rQn9UgucPM6Qqqqq7C9D91dicXFx
bNpxhphPernyFz4m7h747p+b37h0JiYmrKgUf/31l2ltbbWbuHnzpnV0QAj6vlcLiesDCwsLiW0w
ic/lW3H5ruvLdxIh6Mt3eH+SeBF33YaGBttaH5XntPHrINtfmpgpJPzC+3cTx332E1cn4U8IwSMv
BMX58+ftrwsxOTlpf8G4v6TCzdRq4o4zDP3i0vcy1p6enkhDctNxr5c0EIfJJ70k6fvuQdz9C/8q
jUpHgrKmpsb+r66LxcVFKzCFuk7UXQwIQd/34RYnVRZJbTCJz+Vbcfmu68t3EiGYJt97EX/CA/3D
eU4bvw6D/eX7vHf7XHz2E1cn4U8IQYSg+f9N8xIbgQh5/vx5rFMmMQyN4VC6LS0ttvskiZMlCd6+
wbVp00uSvu8exN0/n/B10TgjNeMHAlDjSpaXlzOfASGYtuJKa4P7VXH5ruvL934Iwd3GH19le5SF
YD7PezfPJYn9RNVJ+BNCECH4PyQ6NK4gPClBwmZzczNvw1DLVpRxK+1wF4D7KzttIM0nvSTp++5B
3P0LlzcunStXrpg///wz0yUcdA8HnwEh6Pte3ZWuD+iHRBob3K+Ky3ddX773QwimjRfBJK6A+vp6
+8Mt4M2bNwjBhM+7vLw8sms4nziexn7CdRL+hBBECP4PDTTV7CJ3wKnQwN1g0Kk2fdYsrjjD0PgP
zdIScYNjlZZm1QVpj46O2gCRbyDNJ70k6fvuQdz9C5c3Lh3lXWNhlG9x//59O2su6HYGhKDvew1N
6OvrywwSb25uTmWDPp+TPWrMU1DJJK24fNf15TtMXD6SCkFfvHAnGHz8+NEO+YibLKLyIASTPW9N
FlF3rXjx4sV3k0XSxnGf/cTVSfgTQhAh+D/06hL96nJ/4QZ0dXXZaejar2DozrjNlaaa4DXgN5gu
HzhgruOD1wRo08yw9+/f7yqQpk0vafpx9yDu/oXTi0vnv//+y3ptTDDA9927d1gvQjBxRTw4OGh/
UOjVEppdmMYGfT6nHzo6L2ihSVpxJfEhX77DP7yi8pFUCPriRSAYFMckRBTHwumoslV+9SNQed5N
j8ZhEoK+561Xbl29etXeX9UVinW7jeNx9hNXJ+FPCEGEIAAc6IoYCgOJm/0ez4v9wVGNf4AQBEAI
4r8FhVpbNPkgeJebWrHiJiFgf0D8A4QgAIGQIHxI0NsB9L42dc1pxv+dO3esIMT+gPgHCEEAAiFB
GLA/wP4AIQhAICQIA/YH2B8gBAEIhARhwP4A+wOEIACBkCAM2B9gf4AQBCAQEoQB+wPsDxCCAARC
gjBgf4D9AUIQgEB4AIOwL4/EoMNnf1qlQ6t11NbW/pR8bW1tmdu3b9v3OiofZWVlpre3tyCfSZLV
bgrZTvBfhCAAToQQpKLA/rJw12T+GbS2tpp///3XvthbaN1evdxb21F9fghBQAgCHKGKOGiR0Tqq
1dXVZm5uLmu/Wke03qjWbe3o6Mja9+HDB7tOaVFRkU2joqLCPH78OOuaWqf1zJkz9uXJQUWr9V91
jo6fn5/POv7evXumtLQ0s66rKxLCLSLj4+ORxwZ513qqemHzyMjIka+ICs3+9J27RdmMCNYPlt00
NTWZ1dXVrHQePHhgW/X0rB8+fGiGhobss/cJTe0Po1ZCpeOmPzExYdNXHtrb2+2SgEn9xGfzafwp
1/+78WEJ4La2NnuvtOb11NQUQhAQggBHtUVmdnbWdo0FaLF5ia1gGTRVElroPqCmpsZMTk7a/dok
tlSBu9dUpal9waL23d3dZnp62v6vJdYqKyuzjr906VKmkle+3Io6XBGq0ow6VvnWkm269sbGhvnt
t98QggVof+Hvc9mMRJ1sK7Az2aWElXvOzZs3rY0+efLEipq///7bfg7bRRjZn2xaYi0u7+q6lq3p
+hJW6k5O6ic+m0/jT7n+340PDw8Pm/7+/oyfNDY2IgQBIQhwlCpiVTRBJRVGlV/QZRbgVjK5UKuE
e0235SaoeMNpxh0fVfn5jm1oaDDr6+uZzwsLCwjBAyIEw8+1qqoqS6jpf7XORZ2jz5ubm4nKLbuQ
TUtM6UfI/fv3zcuXL7/Lk9uK9+XLF3P27NnEfuKz+TT+lOv/3fiwWl3de7uffoKGQAgC4EQFWBGr
BSFo8ejp6cnap8ox3H3nVkxC3Xhq8dBYK1XYvgHtca0zUd2Hvv9zfac1fF1UGSIED4YQjBNDuezI
l0aScsuO1TqmVmalPTg4mHV+WEy51/f5SRqbT+pP7v+78eFw3vbTT9AQCEEAnKhAJ4uo8lGXVUtL
i+1OjauAXTRuSq0dGp/1/Plz25VXKELwR1Zw2N/+CsFcNhNnC/kIQZelpaWsVjNfnnx+ktTm0/hT
LgGZjw/77i1CELKeIQ8S4OAGwSTXX1xczDpOA8/dLrYwGovl7l9ZWfGKtfLy8lTdZPkKwfr6ejvm
KeDNmzcIwQMqBGWH4a5ht8V3N0JQk0Jy2aMmVrjnyzcCPn/+bG0/qZ8ktfk0/hRVprQ+rCEU7r1d
Xl5GCEK8EORhAhzMABiVB7VAaNahCA+s1yD9YCC5Nn3WjM0AzdgNZjWqApH48lVW6vZSV5Z48eJF
5MD53QrB8GQR5RsheDCFoOxOs8kDOxwdHbXiai+EoGYjK/2PHz/az5oNrGtpwop7vuxHdqTr3717
11y5ciWxnyS1+TT+5P6/Gx/W5JS+vr6MnzQ3NyMEwS8EgwfKxsaWbCtkEaAuJY1FCl7BElQoAV1d
XbalQi0wGj8VzOQUGlQfDLRXZaQB6z6xpor26tWr9hxdV4PT90MIClVwem2GXouh2ZPhcYMIwYMh
BAPBplY6bZox/P79+z0RgkKzgCUs5QOahKJrua1kOl8C7ddff7UTM+7cuWNbBZP6SVKbT+NP7v+7
8WGh8ZAqt3xFfoIQhERCEAj0gG0cJFQZuzM9sQHsD9/hPgJCEEcDbOOQohYODZ4P3p+mVh53ED02
gP3hO9xHQAjiaIBtHFI061LvSFN3mCYEqDtPghAbwP7SctSHFGADgBDE0QDbAGwA+wNsACEIOBpg
G4ANYH+ADSAEAUcDbAOwAewPsAGEIOBogG0ANoD9ATaAEAQcDbANwAawP8AGEIKAowG2AdjAwbI/
rTMMxCBACOJocKRs49OnT6ajo8OumhCsfjA1NfXd+b6VU/R/+LzwtZOm427Kk1ZGuHXrltna2vou
fS3bpeP0yhh84mAJwbTPer/LzqtiqJ8AIYijwZGyDVW2et+e1uYNltV6/fq1OXfunJmYmEhlWzpG
aWkVj6QiIOn3yqdeCN3W1vbdvj/++MPu+/333/GJAygE0zxrYij2BwhBwNFgD22ju7vbLkQfRmJQ
oi6tELx//77p6enZcyEotEqI1pp10bqpwdJxEq/r6+v4xAEXglHPWmsCaz1cfa8W7DDar9ZEvUB8
ZGQkcm1ercWrlketzVtdXW3m5uYyx+RqoY67ro7TWr9qTXf9BaifEIKAo8GBsA0tbv/x48c9sa3g
mPr6erO6urrnQlCExUFfX5+5e/eu/b+rq8tW2vjEwReC4Wc9NjZmW62DJQM1BGFgYCCzX/vUiqj9
Gxsb5rfffosUghKBz549s//Pzs6asrKyyPz4rqvj29vb7X79KAHqJ4Qg4GhwoGxDlWLS85OM7RMv
X740165d21MhKLE6PDxsK12X0tJS8+HDB/v/ysqKbRXEJw62EMz1rGtra63YcnEFXENDQ1Zr8MLC
QqQQVOvd9PR0ovz4rqvj3R89QP2EEAQcDQ6UbRQVFe2ZbbnHSAhKEOYrBMNbSUmJ+eeff7LWC1Zr
TlNTU9a5zc3NWZNG8InCF4JJnrV+sISPU9duQHiSh8RblBCU3eizRJ5vGIPvutgX9RNCEHA0ONC2
UVNTY7vSwqgSfvz4cd5CUK066iLOVwgGqJXn4sWLZnFx8bvjLl++nFNI6Ht84uAIwSTP2hVfuQi3
bMcJQaFxfTMzM6alpcV2KUcd57su9kX9hBAEHA0OtG2oRURjoML8+++/dpxVvkIwSFuTR3bbNSxR
KnH35MmTzHfqjlO3cLjbTp/1fdBNiE8cHCEY9ayFJnVsbm5Gpq8fHe4Pmjdv3sQKwQCJzrjjfNfF
vqifEIKAo8GBto3Pnz/b9waOjo6aL1++WCH16NEjO/My6NrNVwjqNTLqftuLMYISdhqbpXGAgcjM
NdtZDA4OZiaN4BMHSwjmetZCz7q/v9/apzZ9docFhCeLaF+UwNMEKc0cFpo04rYmaqiEfmQEr1Ly
XRf7on5CCAKOBgfeNtSNe/36dTtLU11heg2GXtIcPj/pZBEXzbLcq1nDytP58+ft/+rSDr+vMECC
Vi05SfONDRSWEAw/6wDNCtfrYTQeUK2G4Vm6mkGu17xojKFm+7rjBt3rqFtYP35k6xKBgSgUmhGs
89xz465LzKV+QggCjgbYBmADBXZt/UgI3i8J2B8gBHE0wDawDWzgEAvB4uJiO/kjeN+fZh27k0CA
GAQIQRwNsA3ABg7ptfXKIA1pUPetxrfeuXMn6/UzQAwChCCOBtgGYAPYH2ADgBDE0QDbAGwA+wNs
ABCCOBpgG4ANYH+ADQBCEEcDbAOwAewPsAFACOJogG0ANoD9ATYACEEcDbANwAawP8AGgCeIowG2
AdgA9gfYAEIQcDTANgAbwP4AG0AIAo4G2AZgA9gfYAMIQcDRANsAbAD7A2wAIQg4GmAbgA1gf4AN
IAQBRwNsAxCC2B/2hw0gBAFHA2wDEIKA/QFCEHA0wD7gaD177A/7A4Qg4GyAjcARfubYH/YHCEHA
4aAA7ITt6GzYHxv2BwhBhCAA/oF/APYHgBAk0ADgHwDYHwBCkEADgH8AYH8ACEECDQD+AYD9ASAE
CTQA+AcA9geAECTQAOAfANgfAEKQQAOAfwBgf4AQBAINAP4BgP0BQhAINAD4BwD2BwhBINAA4B8A
2B8gBIFAA4B/AGB/gBAEAg0A/gGA/QFCEAg0APgHYH8ACEEg0ADgH4D9ASAEgUADgH8A9geAEAQC
DQD+AdgfAEIQCDQA+AdgfwAIQSDQAOAfgP0BIASBQAOAfwD2B4AQBAINAP4B2B8AQhAINACJ/YON
7WduAAhBQAgCAPEFABCCQKAGAOILACAEgUANAMQXAEAIAoEaAIgvAIAQBAI1ABBfAAAhCARqACC+
AABCEAjUAEB8AQCEIBCoAYD4AgAIQSBQAwDxBQAQggRqAADiCwAgBAnUAADEFwBACBKoAQDyjSus
mQsAeD5CEAAQgsQZAIQgIAQB4KiKQQBACAJCEAAQggCAEASEIAAgBAEAIQgIQQBACAIAQhAQggBA
fAEAhCAQqAGA+AIACEEgUAMks2M2NrZkGwBCEBCCgA0D4DMACEECAo8JsF8AfAcAIUgwAMB2AfAh
AIQggQAA2wXAhwAQggQCAGwXAB8CQAgSCACwXQB8CAAhSCAAwHYB8CEAhCCBAADbBcCHABCCBAIA
bBeyWFpa4iYU6H3AhwAhCAQCOLS2+/XrV1NeXp7zvPB27NixzP7Pnz+by5cvm6KiInPixAlz7do1
s7GxkZXGP//8Y06ePGmPuXr1qllfX8f3/8fTp0/NL7/8Ympra+3n48ePH7jyuGntVbo/6j4Q/wEh
CAQCOPK2u7OzY65cuZLIvp88eWK6uroyn3t7e01PT4/59u2b3f7999+s/YODg2ZkZCSzv6+vzzQ1
NeH7/0Mi8NmzZz88xuyXEDzMsZb4DwhBIBDAobRdCbOPHz967VtCrqamxmxtbWW+u3DhglleXs4S
lRcvXsx8LisrM1++fPlO/MTl89WrV+bMmTOmrq4uS3CeOnXKtjp2dHRknbO9vW1u3LhhWxwrKirM
/Px81n61SOo87VdZV1dXY6+ncra1tdlWzJKSEjM1NZV1b4JWPLWMVldXm7m5ucjyfPjwIdNiqnOU
v8ePH2eunWSN27iyR92v8HOLK0+u5x7ePzExYYqLi20e2tvbbQty1LFJnkua+5LkPqR5JsR/QAgC
gQCwXYfnz58nsu+xsbGs1j4hcSGhEf4uF5ubm7Yyb21tjc2nhIbSXFtby1x3fHzcfiehKSEzMDCQ
Oae7u9tMT0/b/2dmZkxlZWVm39DQUFaLpNKSOIm73vDwsOnv77ffqZu7sbEx6964rXizs7NW7EYh
4Tw5OZm5vvIi0Rb1XMKffWXPlf8wvvIkEYLqupaAVhp6hrdv3/YKwbjnkva++O5DmmdC/AeEIBAI
ANvN4xhV3isrK1nf5Wrdy/Wdxg6qJUfbmzdvYvPgttgJiZCw2HQregmM8P6Aqqoq2zIVoP/VshV3
PbWsuecsLCxk3RsJlkDg5IM7xtInBH1lz5X/ML7yJBGCbmueWnjPnj3rFYJxzyXtffHdh90+E+I/
IASBQAAIwZhj3r59a+rr62Mr7zghGKBuWnXdpcmD0oubsBJ3PV/+oq7nIgHiHqcWp6CVTOMjfajr
Vq1jagmVMI0TYeHPvrInea6+8iQRgmERFnUPwy2ne3VffPch7TMh/gNCEAgEgO2mOObevXtWxIXJ
1Q0c1TUs1K3nGyOYRMwlFZ659vlEkO+cQMSou7OlpcV0dnZGXl9j69Qy9uDBA9sFr+7bNELQV/Z8
hGCSe5DmHuUjBNPeF999SPNMiP+AEAQCAWC7KY/RrGJVsmFU6bqTQTSJwJ0VrC4793Uy4a7ZJHlQ
C6LGF0ah195EdUHq3HDXsPtqklzXa2hoyDpHk2Gi7s3i4mLsfZModvOurvU0QtBX9iTP1VeecBq5
8qhyBuiVQa7Yj0or7rmkvS+++5DmmRD/ASEIBALAdlMeo/FYuSYjaOJAMBFBm1p43K45tSK6r5e5
e/eu3dLkQRM+3Gvosys21b2orkHx4sWL7yaLqDUzOHd0dDTrfYm5rqdJDHrNTTC5orm5+buxb5ql
KjRBIa7lq7S0NDMbVgJM3etxgkezaDXmLxBuvrInea6+8rgTLTR7XLN5w3nUNXVu8Az1w8AnBOOe
i+++pL0PaZ4J8R8QgkAgAGw35TGqWHO17kgcSliolU3bpUuXbItRgLqCNatV+zRRJFf3cpI8aLay
WpGUjoSKK0rVCqkXVSuPGmumyRAuwetjtGnG8Pv3773X0/sP1XKp15Voxqp7nLogdR11V+qagQDJ
xcuXL62I1nESK5rQECcENRM2uJdJyp40JsWVJxBOKo9EssoTzqNE26+//mpbeO/cuZP1jKPKE/dc
fPcl7X1I80yI/4AQBAIBYLsA2A73ARCCQCAAbBcA2+E+AEIQCASA7QJ8RyGu+4sPAUIQCAQA2C4A
PgQIQSAQAGC7APgQIASBQACA7QLgQ4AQBAIBALYLgA8BQhAIBIDtYrsA+BAgBIFAANguAOBDgBAE
AgFgu5QTANsChCAQCADbpZwA2BYgBIFAAEfKdvW91mnVGrJ1dXWZ73t7e+26tFqft6Oj47tzHjx4
YNeuPX36tHn48KEZGhqy68BqnVetXesSrPVbVFRkmpqazOrqqtna2jJnz56169G6bG9vm+rq6kT5
0NrHbW1t9rolJSVmamoKHwXiPyAEgUAAkEYItre3W1G1trZmvxsbGzPj4+P2u52dHSuwBgYGss65
efOm3ffkyRMrxP7++2/7WSJQYjBAAnFkZMSmpU1p37hxw+67deuW3e8yPDxsxV+SfOjY/v5+u39j
Y8M0Njbio0D8B4QgEAgA0ghBtdC51NbWWnHlUlZWFnmOPm9ubua8VlVVlW3lC9D/akkUb9++ta2C
wbX099y5c5m0fflQC6ab9sLCAj4KxH9ACAKBACCNEAyjFj19727Hjh2LPCfus3uem37A+fPnbauf
mJycNJcvX06cDzedQEjio0D8B4QgEAgAdiEEc4m3pMIv/Dks1sL7Z2ZmTEVFhf1fYwOfP3+eOB++
tAGI/4AQBAIBQEohKEHmdvXuRggqrXDX8PHjx7OOLy0tteP91C2cJh8NDQ1ZaS8vL+OjQPwHhCAQ
CAB2IwQ1gSOYhKFNnzXbNx8hqHPv3buXSWt0dNSUl5dnHa8JIJr1604ESZIPdSX39fVlJos0Nzfj
o0D8B4QgEAgAdiMERVdXl50NrNY7jdsLZhSnFYIieH2MNs0Yfv/+fdb+T58+2etIzKXJhxgcHLST
T/SKGc0yxkeB+A8IQSAQAGC7APgQIASBQACA7QLgQ4AQBAIBYLsAgA8BQhAIBIDtAgA+BAhBIBAA
tgsA+BAgBIFAANguAOBDgBAEAgFguwCADwFCEAgEgO0CAD4ECEEgEAC2C4APASAECQQA2C4APgSA
ECQQAGC7APgQAEKQQACA7QLgQwAIQQIBALYLgA8BIAQJBADYLgA+BIAQJBAAYLsA+BAAQpBAAIDt
AuBDAAhBAgEA9guA7wBCEAgGANgwAD4DCEEgIADsox2zsbEl2wAQgoAQBADiCwAgBAnUPCYAIL4A
AEKQQA0AQHwBAIQggRoAgPgCAAhBAjUAAPEFABCCBGoAAOILACAECdQAAMQXAEAIEqgBAIgvAIAQ
JFADABBfAAAhSKAGAOIL8QUAIQgEagAgvgAAQhAI1ABAfAEAhCAQqAGA+AIACEEgUAMA8QUAEIJA
oAYA4gsAIASBQA0AxBcAQAgCgRoAiC8AgBAEAjUAEF8AACEIBGoAIL4AAEIQCNQAQHwBAIQgEKgB
gPgCAAhBIFADAPEFABCCQKAGAOILACAEgUANAMQXAEAIAoEaAIgvAIAQJFADABBfAAAhSKAGACC+
AABCkEANAEB8AQCEIIEaAID4AgAIQQI1AADxBQAQggRqAADiCwAgBAnUAADEFwBACBKoAeDIx5Xw
BgAIQUAIAgBCEAAQgoAQBICjIgYBACEICEEAQAgCAEIQEIIAgBAEAIQgIAQBACEIAAhBQAgCAPEF
ABCCQKAGAOILACAEgUANcDj8jO3obIDdY/cIQYQgAOBjPHPuARzpZ44V4KwA+Bfw7Ck7HNFnjyXg
sAD4FmADlBmOqA1gDTgtAL4F2ABlBoQg4LQA+BZgA5QZEIKA0wLgW4ANUGZACAJOC4BvATZAmQEh
CDgtAL4F2ABlBoQg4LQA+BZgA5QZfhRLS0sIQQIVAPxI3/r69aspLy/PeV54O3bsWGb/58+fzeXL
l01RUZE5ceKEuXbtmtnY2MhK459//jEnT560x1y9etWsr68TmyhDQdu9mJqaMufOnTPHjx839fX1
ZnFxMbNva2vL3Lhxw+4rLi42HR0d1hcCvnz5Ym7dumV9QsfI7t392Ew8umcIQSorAPhBvrWzs2Ou
XLmSyP+ePHliurq6Mp97e3tNT0+P+fbtm93+/fffrP2Dg4NmZGQks7+vr880NTURmyhDQdv969ev
TUNDg1lZWbF2Ozk5aSorKzP7//77bzMwMJCx63v37tm0Am7fvm1GR0cz+/VjSGIQm/nx10UIYnQA
4PEtCbOPHz96/U8VWk1NjW0NCbhw4YJZXl7OqlwvXryY+VxWVmZbR1x++eWX2Hy+evXKnDlzxtTV
1WUJzlOnTtkWFrW+uGxvb9vWGbU4VlRUmPn5+az9qoR1nvarrKurq7HXUznb2tpsK2ZJSYltGXLv
zdOnT20Z1DJaXV1t5ubmiK+HzO5bW1vtj5go1GIlO3F9Q/YScPr06az98ou4Vq7DZvc6b3x83JSW
ltrjdd6zZ88S5W+v18pGCCIEAcDjW8+fP0/kf2NjY1mtfUKVhlvhBd/lYnNz01ZsqmTj8tne3m7T
XFtby1xXlYq+U4WqCkqtMQHd3d1menra/j8zM5PVcjM0NJTVIqm0VHnGXW94eNj09/fb79TN3djY
mHVv3EptdnbWil3i6+GyewmYuHFqYSEoURYn9LRfouuo2L3O05CRQNzpPPcHYJL87YcNoDAIVAD4
1i6OUWuguspccrXu5fpOYwf161/bmzdvYvPgtlyI2tra78SmWwmpAgzvD6iqqrKVsFsha0xX3PXU
QuKes7CwkHVvVKEHFTDx9XDavWxYYkctbcHYVneMn0SLuoNldxpnqK5gd+xsGA2ZkHA7KnafK303
rST5QwhSWQFAAQnBt2/f2gHzYXJVfnFdv+oOUrdS2ko5bsJK3PV8+Yu6nosqW/c4CQR9VkWt8ZHE
18Nn9/pOkz3Uih20WLkt2RKF+nEjW9FkE9lEVIvgp0+f7LFq1Tsqdh91T3eTP4QgTgsAP1EIqvVD
Ii5Mrm7gqK5hocrQN0YwSaWWVHjm2pdVMSSoEHMdp/FV6o5raWkxnZ2dxNdDZveyYbfFSqIorutX
42Q1ri6XvV+/fv27mfSH3e59QjCf/CEEcVoA+IlCUDMiVQGEUYXgTgZRN5k7K1jdSW4lGO4CSpIH
tSCqZSYKtchEdZHp3HAXlFuh57qeZou656iSj7o3eqXIQYlbCMHkx7gTngIhqC7iKB49evTd2Fe1
BKpVMTyc4ijYvU8I5pM/hCBOCwA/UQhqbFIwqNxFkz+CAebaHjx4kNVtpFZE9/Uyd+/etVuaPGhg
uXsNfXbFpsZeqdtKvHjx4rtB88FYLm16pYf73rhc19OrQvSam2DQfHNzc9ZxSl8zKEV4EDzx9XDY
vcbCaXNfD+MOjZANSPyJDx8+2B9EGlMX8N9//5nz588nfmfmYbN7nxD05U+iW2MMXbGIEMRpAeAn
CkEF/VytDxKHqjD0a17bpUuXsgbVq2tMsxO1TxNFcnUvJ8mDZiuru07paDaiK0rVCqnB/MqjBqG7
FXIgRoOJKhrk//79e+/19OoQtVzq1R0aH+Yep+4xXSd4LUZQORJfD5fdS6ioRTuwuXfv3mX2ycY0
uSIYIxieRHH27NmcL2M/KnbvE4K+/Gl2dBBTEII4LQDgW4ANUGZACOK0AIBvATZAmQEhiNMCAL4F
2ABlBoQgTgsA+BZgA5QZEII4LQDgW4ANYPeAEMRpAQDfAoQgdo/dIwRxWgDAtwAhCAhBbgdOC4Bv
ATZAmQEhCDgtAL4F2ABlPnAsLS0diWsiBAlUAIBv7Wu5j9o9QQgejvvnW21DK35o5Y/a2tp9u6bv
XhSSrSEECVQAgBDkniAED8398+VDIlBrAe/nNQ+SLSEECVQAEONbQeuB1g+trq42c3NzmX1a8F1r
gGoB+IqKCjM/P5+VntYe1VqsWnM1oLe3165TqvVDOzo6vrte3H6lOT4+bkpLSzPrmYYrtLjztRZy
W1ubXZu1pKTETE1NeYWgFrYPynjx4kW7XqvWPK2pqfnueK2brDVkt7a2iK8HvMz52G84rVzHyjZk
I1oH2EW+JP8SHz58sOsGy+Zk4/Ktx48fJ/ID39rFUfuDdX11zaamJmv3vnsRl6b+ai3mKF91rx0X
YxCCQKAC+Mm+5Qbw2dlZU1ZWltnX3d1tpqen7f8zMzOmsrIyK7329nYrvtbW1ux3WqReFZi+k2iS
ENPi8QG+/UpTFWRQSSlfyl/S84eHh01/f7/dv7GxYRobG71CsKGhwayvr9tzHj16ZG7evGn3NTc3
f1dh6dp///038fWQCMG09uumFXfsrVu3zNDQUNb1ZJsSjkI/MiYnJ+252kZGRqwIS+oHabtllRdd
I7ie8q4fP3H3wpemPl+6dClRHuNiDEIQCFQAP9m3VAEFYi+MhJ8qh6j03FYFoTFJ4ePdoO/bnytN
N9++89WaoZaXALXu+YSgjglQ2sG4KgnflpaWrOOV/ps3b4ivh0QIprXfpLb49u1b2yoY7Nffc+fO
fXc9F7WWJfWDtEKwqqoqyy/0f3Fxcez1kgjBpHmMizEIQSBQAfxk39IvdO1TxdbT05O1z/2FnyQ9
HR/uRnIrON/+qK6uNOm7qAJOO0bQTUPdXqrUA1GZq9uM+HpwhWBa+01ji+fPn7cthkKtf2rhc1FX
rFrcW1tbrVDzCb3dCEE3X7nsPIldJBkjGJXHuBiDEAQCFUAB+JYqpaAFrLOzM28hmKvCSbPfV7n4
zs+V37RC0J0d2dfXZ7v5hLrS7t+/T3w9xEIwjX36jpU/aeyf0Li458+fZ/ZNTEzY1vYHDx7Y79Ud
u59C0OcX+y0E42IMQhAIVAAF5FuLi4tZx5WXl8d2DYdRhbe5uRmZvm+/r3Lxna/xfm4X2PLyslcI
Bi1+QueqSy9A4ww1uF5jCDUpIDwBgPhaGGXKZ2Z4PvabxhaFWpQ1NlDdwi6azOSeu7Kysq9CUHkN
dw27P3h+hBCMijEIQUAIAvxk31LLhGb1ifCAb3VdqVtHvHjx4rvJImE0KD2YrKFNnzVDMel+X+Xi
O19dcGrFCyaLaMKHTyRcuHDBfPr0yZ6jtIPJIgFqCfz999/tYHria+EKwajZsmmEYBr79B0rNHlE
s9fdCSeBQAxmCevHSn19fSohqB8nGp/niru4silvmuEb5HV0dNT+yEtjF+FrphGCcTEGIQgIQYCf
7FvqstEYpeAVEEHAFmoBu3r1qv1ex7gTK6LS6+rqsi0eanHQuKjwLMS4/b7KJUn6g4ODdiC8WvA0
O9InBHWMjlV6EoXhAfB6ZY6OO8grK4TvZZR4OqxbGn9IY58+W9QPDO3TjxKXly9f2okl8iuJJE2k
SCMEJSyVbtSLpXOdH7w+Rpt+3OgVSWnq3fA10wjBuBiDEASEIAC+VdCoclcLDjZQuGXKp0UQjmbs
wxoIVAD4FiRG3Whq9fkZMx2xgXRCELsHhCCVFQDgW3uKxkWpu/igTxI5yjaA3QNCEKcFAHwLEIKA
3SMEcVoAfAuwAcoMCEHAaQHwLcAGKDMgBAGnBcC3ABugzIAQBJwWAN8CbIAyA0IQcFqAo+FbcS9K
PgwvUd7vMhyke4QQBIQg4LQA+FYW4dUJ3OPi9u2WDx8+ZC1Zt19xIWr1hb1iv9Mnvh6MMlN3IQQB
ZwI4kL6V5mW8e+mfWvtUy17td1zY75hykGIWQhAQgoDTAuBbWd+Fl+WKWo82Vxq9vb12nV6tX9rR
0ZG1T+uJal1RrS9aXV1t5ubmsvY3Nzeb//77z/6v1kGt1aoXOOuciooK8/jx46x8ag1grZGqYy5e
vJi17nHUtaLKoLVPz5w5Y+rq6hJdf3t7O3Nt7dP6w1HpE18Pzg+gsB1E2fTW1pY5e/bsdy8Wl13I
3tL4xrlz5+waxGJlZcWe9/r1a/t5fX3d7geEIA8MAH5ohRgZNGP2jY2NmfHxcbsM287OjpmamrIL
0wdIUD179sz+Pzs7a8rKyjL7VKGePn0687mmpsZMTk7atLSNjIzYCtq9bkNDg60otf/Ro0fm5s2b
ia6Vqwzt7e02Ha0jnOT63d3dZnp62v4/MzOT1aVNi+DBtfuwHcTZ9K1bt8zQ0FBWGsPDw1bwpfGN
69evW/sVDx8+tEMLdHzwWT84ACHIAwOAgheCtbW1tqJzcQWYhFQgnsKowlOFGIda99zrui2Auq6u
n+Raucqg1kUf7vUl/MJlRQgefLsP20GcTb99+9a2Cgb79Vetd0EaSX1jYmLCikrx119/mdbWVrsJ
/biRaASEIA8MAApeCKoVLtw16oontczpO1WKPT09WelIBIaFm7rp1PKmSrGqqio2H8H1k1wr6TjH
uOu710IIHk67T2LT58+fty19Qi3IGk6Q1jckKNUCLdStvLi4aAWm0LADdRcDQpAHBgAFLwTdCjIK
iSt1pba0tJjOzs7M9+oWdsdbqZVErW4PHjwwz58/t111PiEYnq0bda0kQtB3fYTg0RCCPpuWfUms
BSJOtpKPb8j+NzY2MgKwtLTULC8vZz4DQpAHBgAFLwRVEW5ubia6tlo9gnM1kUNizeXkyZNZaQWD
6N3rqiUlQIP0oypN91pJhaDv+uXl5XQNHwEhmMSmJdo0NjA8qSONb1y5csX8+eefmS7hoHs4+AwI
QR4YAPww39JMWI1zkrgKHxe3TwPn+/v7MxMs9LmpqSmzXy1sms0rNJEjaFXTK2P06phw5RrM0lXL
SH19/Xdi7sKFC3a2pa6l67qTRaKu5StD0uury1jdz+LFixdZk0XC6RNfD64Q9Nm00KSPkpKSrIlR
aX1D9l9cXGxGR0ft5/v371s7CrqdASHIAwOAH+ZbqtDUzRp0tbrHxe0TXV1dtjVN+zVeKph9KdRV
q7F26iaTMAuEmkSUXtfi8vLlSzuYXsdpv8YPhoWgZlbqdRy6lkShO9A/6lpJypDk+urGvnr1qt2v
67gTV8LpE18PrhD02bTQjxHtU9duXHpx6ei1Se5rY2RP+vzu3TsCFUIQEIIA+BZgA5QZEII8MADA
twAboMyAEMRpAQDfAmyAMgNCEKcFAHwLsAHKDAhBnBYA8C3ABigzIARxWgDAtwAboMyAEMRpAQDf
AmwAuweEIE4LAPgWIAQBu0cI4rQA+Ba+hQ0gBAEhCDgtAL4F2ABlBoQg4LQA+BZgA5QZEIKA0wLg
W4ANUGZACAJOC4BvATZAmQEhCDgtAL4F2ABlBoQg4LQA+BZgA5QZEIKA0wLgW4ANUGZACAJOC4B/
Ac+essPBePZYAg4LgI/hYzxz7gEc0WeOFeCsAPA/P2M7Ohtg99g9QhAhCADEF+ILwNGOAdwCAjUA
EF8AACEIBGoAIL4AAEIQCNQAQHwBAIQgEKgBgPgCAAhBIFADAPEFABCCQKAGAOILACAEgUANAMQX
AEAIAoEaAIgvAIAQBAI1ABBfAAAhCARqACC+AABCEAjUAEB8AQCEIBCoAYD4AgAIQSBQAwDxBQAQ
gkCgBgDiCwAgBIFADQDEFwBACBKouQkAQHwBAIQggRoAgPgCAAhBAjUAAPEFABCCBGoAAOILACAE
CdQAAMQXAEAIEqgBAIgvAIAQJFADABBfAAAhSKAGACC+AABCkEANAMQXbgIAQhAI1ABAfAEAhCAQ
qAGA+AIACEEgUAMA8QUAEIJAoAYA4gsAIASBQA0AxBcAQAgCgRoAiC8AgBAEAjUAEF8AACEIBGoA
IL4AAEIQCNQAQHwBAIQgEKgBgPgCAAhBIFADAPEFABCCQKAGAOILACAEgUANAMQXAEAIAoEaAIgv
AIAQBAI1ABBfAAAhSKAGACC+wB4/f7ajsyEECdQAAMQX4NnzzBGCOCsAAPGF5w5H/dljCTgsABBf
gGcOR9QGsAacFgCIL8AzB4Qg4LQAQHwBnjkgBAGnBQDiC/DMASEIOC0AEF+AZw4IQcBpAYD4Ajxz
QAgCTgsAxBfgmRc+S0tLPHSEIE4LAEB8gaTPfHp62nuc9k9NTcWLDM8qF1VVVWZ1dTXr/MePH9v9
MzMzWd/rOB2fluPHj++tcDoEPoMQJFADABBfeOY5+fjxo2lqakokBOvq6szXr1/zFk1dXV3m/v37
Wd+1t7ebxsZGc/v27azvddzdu3d/io0fNj9BCBKoAQCILzzznLS0tJh3794lEoISZz09PXkLwfn5
efP7779nfadWv//++++71j8dp+Nz8fTpU/PLL7+YY8eOmerqajM3N5e5frgVMucya8533759M21t
bebkyZOmpKTEtnrGlam3t9ecOnXKnDhxwnR0dCTKF0IQCNQAQHyBgnvmfX19ZmRkJJFtBPvr6+uz
unfTdqNKbEl8ifX1dVNZWWn/r6ioMGtra/b/nZ0d8+uvv0amIbH17Nkz+//s7KwpKyuLzINPCA4P
D5v+/n6bp42NDds6GVWmsbExMz4+bo9VHiUaBwYGEuULIQgEagAgvkDBPPPXr1+bCxcuJLaNYP/L
ly/NtWvXIoVg3BhB8eeff9qWMyEhFXQJ6+/k5KT9X+MFb968GZmXM2fO2HGNScrrE4Lq7t7e3s58
XlhYiBSCtbW1GREb4Iq9uHwhBIFADQDEFyiIZ761tWUFkFrk0gpBISEoQZhLCPrQ5BCNCwzSUcuZ
0N9AYKqrVsdFoWN1LQmzuK7qJEJQrXguEnpRZdKxYYGrbuAk+UIIAoEaAIgvUBDPXK1tjx49SmUb
7n5NMFEXcT5CUF2q5eXl9n+3m1h/NfYu2O+20uXi1atXtuVQYxw7Ozv3TAjGlckVfWnzhRAEAjUA
EF+gIJ55ki5cXzpq8dLkkXxetXL58mVz/fp188cff2R9rwki+u7SpUuJy7e4uBibh/DnlZWVrO8a
GhqyROfy8nJkepoAsrm5mVe+EIJAoAYA4gsU7DNP0yIo9BoZdYHmIwQDAanJF0m+D6MJJsE4Q03O
cFv1ioqK7GSWQNy5EzjUkikR6uZT4xI1aSaYLNLc3BxZpqGhoczEEm36rFfvJMkXQhAI1ABAfIFD
IwRFrletJGlp1OxgfSdh5qLP+j780ukw6n7V62bUVSuxFYgvoVm8eql08GLpQJDpWHU569hwfgYH
B01xcbHtmpYIjRO3eheiXjWj9CUqg5nOvnwhBIFADQDEF+CZA0IQcFoAIL4AzxwQgoDTAgDxBXjm
gBAEnBYAiC/AMweEIA+MmwAAxBfgmQNCEKcFACC+AM8cEII4LQAA8QV45oAQxGkBAIgvwDMHhCBO
CwBAfAGe+T6ztLSEEAScFgCIL8Az369r/ezz49ILVio5iL6EEMRpAQCILzxzhOAepo0QBAI1ABBf
4EA/897eXru+7okTJ0xHR0fm+2vXrpkXL15kPmvN3IsXL9r/t7e3zY0bN0xRUZGpqKgw8/PzuQVH
juu633379s20tbXZdXtLSkq+W7c4Ln9Jz4/i3Llz5tOnT/b/lZUVe97r16/t5/X1dbvfzW+udZP1
9969e6a0tDSztrDWNUYIAoEaAIgvUPDPfGxszIyPj1tBtbOzY4XUwMCA3be2tmbq6+vtvq9fv5qy
sjLz9u1bu6+7u9tMT0/b/2dmZkxlZWVeQnB4eNj09/fba2xsbJjGxsas/XH5S3J+HNevXzePHj2y
/z98+NB2++p6wWcJXV959PnSpUtmdXXVfpYIlBhECAKBGgCIL1Dwz7y2ttaKKBcJPleISWxJfN2+
fTvzvYRf+Lx8hGBdXZ1tXQxYWFjI2u/Ln+/8OCYmJsytW7fs/3/99ZdpbW21m7h586YVnUmEYCAC
C92/EIIEagAA4gvPPAu1XoW7PNXFGRaLxcXFmW7U4LxEgsMjBMPpSPSF98flz3d+HGrdrKmpsf9X
V1ebxcVFc/bsWftZ3d3qLk4iBA+KfyEECdQAAMQXnnkWYdGXC3V9qgXwRwjB8H5f/nzn+zh9+rTt
Ug4EoMb6LS8vZz4jBIFADQDEFzi0z1wtYZubm5HnjY6O2jF6Dx48yOoaLi8vz6trOJiUEdDQ0JDV
tSsR5u735c93vo8rV66YP//8M9MlHHQPB58RgkCgBgDiCxzaZz40NJSZbKFNn5uamuw+TRb57bff
skTZu3fv7P+aLDI7O2v/18ziqMki7izajx8/msuXL2ftn5ycNH19fZnJHs3NzVn74/KX5HwfmvGr
bm8JXnH//n07E1riN1d5tE9jAgPxiRAEAjUAEF/gQD/zrq4u+/oVzZqVUJMAFFevXs16fYz+136h
WcTaL6FXVVVlJ2nkulYwi1ZdvGpF1CtownkZHBy0YkyviNHklPD+qPwlPT+u7P/991/Wa2OCySaB
4A2fr0kzykfwYmmEIBCoAYD4AjzzAkYzggEhiNMCABBfeOZHEHVjA0IQpwUAIL7wzAEbQAjitABA
fAGeOSAEAacFAOIL8MwBIQg4LQAQX4BnDghBwGkBgPgCPHNACAJOCwDEF+CZA0IQcFoAIL4AzxwQ
goDTAgDxBXjm3EeEIGBsAEB8AZ459xEhCBgbABBf4GA9c33/6tUrc+bMGVNXV5f5vre3167de+LE
CdPR0ZF1zocPH+yav0VFRXYd4YqKCvP48ePMfq0nHKwvXF1dbebm5rLO/+eff2y6Or+pqcmsrq5m
5Wd8fNyUlpba85WO1itOmnaafPqu9e3bN9PW1mbXOS4pKTFTU1OxvuO7HkIQCNQAQHyBghOC7e3t
VvSsra3Z78bGxqxA0nc7OztWAA0MDGTOqampMZOTk3a/tpGRESskA1xBNTs7a8rKyjL7hoaG7PHB
ubrWjRs3svIjMRWIQ6Wj9JKkHcaXT9+1hoeHTX9/vz13Y2PDNDY2xvqO73oIQSBQAwDxBQpOCLot
cqK2ttYKGZc4wSXUohYg8TM9PZ3zuKqqKrO9vZ35rP+Li4tj8+PmPS7tJLj59F1LLaRuXhcWFlL7
jns9hCAQqAGA+AIFJwTDqFVM37tbWNCoO7m7u9u0trZaceemo5Y6fZag7Onp8QojtxUuV36Spp2L
uHz6ruXmS0gc+3wn7noIQSBQAwDxBQpeCPpasSYmJkxlZaV58OCBef78ue1SDqcjQTQzM2NaWlpM
Z2dnpLj6TqB4xFlc2mnzmVYI+nwnyX1BCAKBGgCIL1DQQlCTMDY3NyPT0uQJd//Kykpk+ouLi1n7
lHa4a/j48eOphGBU2mnz6btWQ0NDVl6Xl5d3dT2EIBCoAYD4AgUvBDWhI5gkoU2fNbs3QLNsg9mw
Ekf19fVZ6ahVTLN7RXgChtK6d+9eJu3R0VFTXl6eWJzFpR3Gl0/ftTTxo6+vLzNZpLm5OdZ3fNdD
CAKBGgCIL1DwQlB0dXXZFi611mlmbTCjWLx8+dJOHpEIkzDT5A03HXXdanxc8EqWQLgFBK+P0aYZ
w+/fv08sznxpu/jymaT1cXBw0E5m0at0NMM5znd810MIAoEaAIgvwDMHhCDgtABAfAGeOSAEAacF
AOIL8MwBIQg4LQAQX4BnDghBwGkBgPgCPHNACPLAAACIL8AzB4QgTgsAQHwBnjkgBHFaAADiC/DM
ASGI0wIAEF/gpz3zpaUlbvABuFcIQZwWAID4wjPPQitzaCWM2travNN21wr+Ufala4Q3rTZS6ITv
FUIQCNQA8EPjSniDo12nSARqzd69TPtn2NWTJ0/ssnjU7QhBhCAAAEIQEtQpuWzBt/6u/td6v2fO
nDF1dXWRady7d8+UlpZm1gQOi83e3l67fq/WG+7o6Pjueu41fHz79s3U1NSYra2t2PLnStOXj4mJ
CbvWsPa3t7ebr1+/Zh0TrJtcVFRkmpqazOrqaqp7FbTI6j5VV1ebubk5hCAgBAHgx4hBoE5J0poX
FoISRBJfa2trkWlcunQpI4okAiV2AsbGxsz4+LhNY2dnx0xNTZmBgYHYa8Sh9HytgbnSTJIPdZmr
HDpGovH27duZ/UNDQ2ZkZMTu06b0bty4kepeuSJ5dnbWlJWVIQQBIQgACEEoXCHotnpFpRF3jMSV
xJGLK4BynR+HWgNXVla85Q+nmSQf8/Pzmc9fvnwxZ8+ezXyuqqoy29vbmc/6X62Hae6VWgunp6d/
uA3g/QhBAEAIcjOoU/ISgrtNQ61gcRM90tjm27dvTX19fV7lT5KPsFB0WzZzTU5x9ye5V2oFDFoe
e3p6EIKAEAQAhCAcbiHom92bxjY1FlHj9PIpfz75cIWe+3++90poHOHMzIxpaWkxnZ2dCEFACAIA
8QUKQwiqy3WvhaAmRWxubu6JfV65csWKqHzKnyQfi4uLmc+fP382J0+ezDo/3DXsvh4mqRAM0LX2
0zcRggRqAADiC8889nt38sLHjx/N5cuXvUJQM2Y1Fi4QRT4BpEkW/f39mUkW+qwZt/nYp8b0JZlQ
kivNJPnQ542NDbv/7t27Vni656tFMjh/dHTUlJeXp7pXlZWVduawCE+qQQjitNwEgB/gZ2xHZ6NO
8X8fiBF1m0rUSKT4hKBm2qolLGgNS9ISplm+al3TORKbrphL86yU1/A4vjTl9+Xj8ePH5tdff7WT
Ou7cuWNbBV2C18do04zh9+/fp7pX6hbWpJPgNTuBKEQIAkIQAB8Dnjll554hBDFAAMC/gGdPubln
CEEMEADwLcAGKPMP4WeuC4wQBJwWAN8CbIAyA0KQBwYA+BZgA5QZEII4LQDgW4ANUGZACOK0AIBv
ATZAmQEhiNMCAL4F2ABlBoQgTgsAR8G3lpaWCiqd/U4TGzgaZT4ItoMQBJwW4JD71tevX7OWiUq7
P0ArBGilgNra2vRB2pPHvXqtxX68HiOcZtJY9iNjHkIwOWnseHp6elf3di/sMY0fIQQBIQiAb2Wx
s7Nj1xKNOsa338Vds3WvK7C9ig/7EWfyTRMhWJhlTmrHWpdY6/Lu5t7uxXOh7kQIIgQBIG/fUkWm
Ci3qGN9+9xrhNW59668mFYJR6+f29vaaU6dO2TVPOzo6Mt9fu3bNvHjxIvNZLTwXL15MtA7vhw8f
7PqrRUVFVhBUVFTYtVfdvGitVK3DWldX5y339va2XY9V6Smt+fn5yDJHlScoQ7AebnV1tZmbmyO+
7qLMwXq5ei6y8dXV1Vhby0VLS4t59+6d97ioZ5ePz2iN4ba2NrtWcElJiZmamor1o/20KYQgIAQB
DoFvPX/+PPYY3/646+yVEMy1f2xszIyPj9uKUa2WqhC1uL1YW1sz9fX1dp+6tcvKyszbt28TXaem
psZMTk7ac7WNjIxY0efmo7293e7TdXzl7u7utt2HYmZmxlRWVuY8Lq484Vaq2dlZWybia35lHhoa
ss81eMa69xLrae5VX1+fTSPJ8XHPLq3PDA8Pm/7+fpvvjY0N09jYGOlH+21TCEFACAIcIt/ai67Z
HykENX5LFZyLW5GpElSlqYrv9u3bu4ozajFxzw9aj5KUW8IvnM9cx/nKIzEaCEri6+7KXFVVZVtq
A/R/cXFx4nv1+vVrc+HChcTHxz27tD6jVmg37wsLC5F+tN82hRAEhCAAQvCnCUG1ZoS71lzBFlSE
quA/ffqUqhzq+lVLXmtrqxUNvnzGlVv5TFImX3nUYqPvVKaenh7i6y7KHLaT8HOKu1dbW1tWjK2v
rye+t3HPLq3PhO1JQi/KPvfbphCCgBAEQAjuuRCMGqMVTitXZR7m0qVLtkUujRCcmJiw5zx48MB2
i6v790cIwSTlkUBV97LGpnV2dhJf8yxzrmeS9EfJzZs3zaNHj1Lf26hnt1shGJf3/bYphCAgBAEQ
gqmE4MrKyp61CGpw++bmZuTxo6OjdnyUBF2armENwnfTjctzknLrtTtJuoZ95XFZXFxMHS8Rgtm2
E+4adl/jkmbiUtKJJVHPLq3PNDQ0ZOV9eXk5Mr39timEICAEARCCsce4g9E181izcfMVgprdqbF5
QSWoAf/BoHlt+qzZn0KteL/99ltWhajZnbnSCVNaWpqZJaxKVpNOfPkMpxmeLKIuOKGZzFGTReLK
I3SeZnkK3dO4lkbia3yZdW/v3buXudf60eC+J3OvRXbcswvbjs9nNJFJE1WCySLNzc2R9rnfNoUQ
BIQgAEIw9pigclEXlSpaVTr5CkFN+lCrjdty09XVZVvw9J0qzGAW79WrV7NeH6P/tT8qHZeXL1/a
AfXKtyrK8AuDc+UznKZ7jGYtKz9KT+MNNbg/Kq2o8gh14el83UulFVTgxNf8yhy8PkabZgy/f/9+
34Rg3LML247PZ8Tg4KAd+6rXwmhSVJx97qdNIQQBIQiAbwE2QJkBIQg4LQC+BdgAZQaEIOC0APgW
YAOUGRCCgNMC4FuADVBmQAgCTguAbwE2QJkBIQg4LQC+BdgAZQaEIOC0APgWYAOUGRCCgNMC4FuA
DVBmQAjywAAA3wJsgDL/BJaWlhCCgNMC4FtHo+xaSUErKtTW1mIDR7zMB+n+7Gdeo1bcQQgCgQoA
3zp0ZXfXdcUGEII8y8NnJwhBAhUAxPjWhw8f7PqjWvheoqiiosI8fvw4sz9oMdNapNXV1WZubi7R
PtHb22vXQtVarh0dHVn79ivdb9++mba2Nru2aklJiZmamoosu753t4BgDVrdk6amJrO6upp1jtZn
PXPmjKmrqyO+HtAyJ7GTODvz7VdaDx48sOsBnz592jx8+NAMDQ3Z6+X68bFXNh1ce3x83JSWlmbW
EA5fL8rGo3wCIQgEKoBD6ls1NTVmcnLSVjbaRkZGrMgJcCuR2dlZU1ZWlmjf2NiYrYyU5s7Ojq28
BgYG9j3d4eFh09/fb/dvbGyYxsZGb6Xpospa9yC4H7rejRs3so5vb2+3+9bW1oivB7TMPjvx2Zlv
v9K6efOm3ffkyRMr4v7++2/7WbYtG99Pm9aPu0Dcha+XxMYPqw2gMAhUAPhWAtSKECBROD09nfO4
uH0ac6dKxsUVdPuVrlrptre3M58XFhZSCcGqqqqs8/W/WnXc490WQuLrwSyzz058dubbH7YTfd7c
3MyZr/2w6bCNuscnsXGEIBCoAI6Qb6mrs7u727S2ttpKwj1WLXL6rMqqp6cn67y4fWqBCHczuQJz
v9J1Wz6EKtg0QtBNK1eaBzlGIQRNYjtJYmdx+8PXjfu83zYd/u4w2zhCECEIACl9a2JiwlRWVtrx
TM+fP7fdneFjJRRnZmZMS0uL6ezsTLQvV2WTS4DudbrhStMXV8L7fOcjBA+nEEwilnw/GJIKv7TX
2q1N5xKeh9XGEYIIQQBI6Vsau+R2Wa2srEQeu7i4mHifJnm46caxl+k2NDRkdXstLy+nqjSVfrjb
zH2dBkKw8MqUVhQlsROfnfn2pxGC+23Tua53WG0cIYgQBICUvqWZhcEsYVUw9fX1WceqtVCzeEV4
0HncPg1IDwa4a9NnzU7c73Q18aWvry8zsL65uTn1ZJF79+5l0h8dHTXl5eUIwQIXglGzXaPK7LMT
n5359qcRgvtt07muF2fjmkmsMYauWEQIAoEK4JD61suXL+3AdIktCTBN0nCPVRetxg0Gr6EIBJpv
n+jq6rItjmpt0CxGd5btfqUrBgcH7eB3vY5DMyLTVprBqzW0aTbl+/fvD5UQjBJPh3WLwmcnPjuL
259GCP4Imw5/F2fjmrGsfByWF0sjBBGCAIBvgaFFELB7rIFABYBvATZwCIUgdg8IQQIVAOBbgA1g
94AQxGkBAN8CbAC7B4QgTgsA+BYgBAG7RwjitAD4FmADlBkQgoDTAuBbgA1QZkAIAk4LgG8BNkCZ
ASEIOC0AvlWwLC0t8RCJr5QZX0AI4rQA8CN9K9+X86Y5L+pY9//DssoB8fXglrlQ7h++gBDEaQHg
pwjBH3HtqGOJDcRXhCC+gBDEaQFgH3yrt7fXrmGqdUc7Ojqig2goDZ2n9VFPnz5tRkZGYlv2tIi9
1jTVgvYXL140CwsL3mtErY1bU1PzXRl2dnbM2bNnzdbWFg+b+Jroh4XWtD5z5oypq6tL7QtRx8r+
ZIdfv37NOnZ7e9tUV1fb/z98+GDXE5YvaC3tiooK8/jx46zrjI+Pm9LS0sx628+ePcvpC4AQJFAB
wK58SwvYq9L59u2bFVNTU1N20XmfSNM5nZ2d9ryNjQ3z22+/xQq6hoYGs76+bo9/9OiRuXnzZmIh
GP6/ubnZzM3NZZVD+fn777950MTXxEKwvb3d2uPa2lpqX4g79tatW2ZoaCjresPDw1Y4Cv2QmZyc
tOdq048oCVL3OhKK+vEkJAIlBqknEYIEKgDYc9+qra21lZFLWVmZV4wFwi5ALXxxIs5tAdT1dN18
heDMzIxpaWnJyrNadd68ecODJr4mFoKB0MrHF+KOffv2rW0VDPbr77lz5767nota/uLylu9YXUAI
EqgAINa31NIQ7m4KV0q5/g8PWFdll0TEudfNVwgKdZupwg1EqNu9B8TXJEJwN77gO/b8+fO2xVCo
9U8tfC7qlu7u7jatra2mqqrK6y8IQYQggQoA9sW33MrLG0RDFeFuhKArJPMRgn19fbYLTmjs4f37
93nIxNddCcE0vuA7Vq3WGvsnNDbw+fPnmX0TExOmsrLSPHjwwH6vrmmEIEIQMHCAn+JbqqQ2NzdT
C8H6+no7NjBA3bJxIi5ovRMaOK+us90IQV1bg+3VPa0B++HB+UB8TSsE0/iC71ihVmuNDVS3sIsm
WLnnrqysIAQRgoCBA/wc39Kg9v7+/szAdX1uamryVkDhySI6J07EXbhwwXz69Mker+ulnSwi0adx
UxKRAWoJ/P333+2gfyC+7lYIpvEF37FCk0dKSkqyJpwEAjGYJby8vGx/VKURgrl8ARCCBCoAyNu3
urq6bCuFums1limYRelriVD3rFrjVNlpFmVcd6/261gdI1HoDoZPIgRVmepc9xrz8/P2GFZaIL7u
hRBM4wu+Y4V++Gif23IuXr58aSeWaHiFuoinp6dTCcFcvgAIQQIVAPxU31LXrNvd+yNQxavWFSC+
UmZACOK0APADfau4uNgOiA/eo/bPP//YruIfha6rFpmenh4eLvGVMgNCEKcFgB/pW5rtqFe2qHtK
K4vcuXPHCsIfhcZJqYuZSSLEV8oMCEGcFgDwLcAGKDMgBHFaAMC3ABvA7gEhiNMCAL4FCEHA7hGC
OC0AvoVvYQMIQUAIAk4LgG8BNkCZASEIOC0AvgXYAGUGhCDgtAD4FmADlBkQgoDTAuBbgA1QZkAI
Ak4LgG8BNkCZASEIOC0AvgXYAGUGhCDgtAD4FmADlBkQgoDTAuBbgA1QZkAIAk4LgG8BNkCZASEI
OC0A/gU8e8oOhfbssQQcFgAfw8d45twDOKLPHCvAWQHgf37GdnQ2wO6xe4QgQhAAiC/EF4CjHQO4
BQRqACC+AABCEAjUAEB8AQCEIBCoAYD4AgAIQSBQAwDxBQAQgkCgBgDiCwAgBIFADQDEFwBACAKB
GgCILwCAEAQCNQAQXwAAIQgEagAgvgAAQhAI1ABAfAEAhCAQqAGA+AIACEEgUAMA8QUAEIJAoAYA
4gsAIASBQA0AxBcAQAgCgRoAiC8AgBAkUHMTAID4AgAIQQI1AADxBQAQggRqAADiCwAgBAnUAADE
FwBACBKoAQCILwCAECRQAwAQXwAAIUigBgAgvgAAQpBADQBAfAEAhCCBGgCIL9wEAIQgEKgBgPgC
AAhBIFADAPEFABCCQKAGAOILACAEgUANAMQXAEAIAoEaAIgvAIAQBAI1ABBfAAAhCARqACC+AABC
EAjUAHAA4kp4AwCEICAEAQAhCAAIQUAIAsBREYMAgBAEhCAAIAQBACEICEEAQAgCAEIQEIIAgBAE
AIQgIAQBgPgCAAhBIFADAPEFABCCQKAGOBx+xnZ0NgBACCIEAQAf45kDIASBgAWAfwHPHgAhCAQr
AHwLsAEAhCAQqADwLcAGABCCQKACwLcAGwBACAKBCgDfAmwAACEIBCoAfAuwAQCEIBCoAPAtwAYA
EIJAoALAtwqSpaUlHjrxFQAhSKACgDjf+vz5s7l8+bIpKioyJ06cMNeuXTMbGxux6UxNTcWm71vl
oqqqyqyurmad//jxY7t/ZmYm63sdp+PTcvz48T29Z4chNhFfASEIBCoAfCuL3t5e09PTY759+2a3
f//913R1dcWmU1dXZ75+/Zq3aFL69+/fz/quvb3dNDY2mtu3b2d9r+Pu3r37U2LJYYtHxFdACAKB
CgDfyuLChQtmeXk583lnZ8dcvHgxNh2JM4nHfIXg/Py8+f3337O+U6vff//9913rn47T8bl4+vSp
+eWXX8yxY8dMdXW1mZuby1w/3AqZK0/udxLBbW1t5uTJk6akpMS2esaVSQL61KlTthW1o6MjUb6I
rwAIQSBQARSUb0n4SASFv/OlU19fn9W9m7YbVWIruO76+rqprKy0/1dUVJi1tbWMKP31118j05DY
evbsmf1/dnbWlJWVRebBJwSHh4dNf3+/zZO6xtU6GVWmsbExMz4+bo9VHiUaBwYGEuWL+AqAEAQC
FUDB+JZES5Lvwum8fPnSjieMEoJxYwTFn3/+aVvOhIRU0CWsv5OTk/Z/jRe8efNmZF7OnDljpqen
E5XXJwTV3b29vZ35vLCwECkEa2trvxPPrtiLyxfxFQAhCAQqgILxLXVf5iMEhYSgBGEuIehDk0M0
LjBIRy1nQn8DgamuWh0XhY7VtSTM4rqqkwjBcJkl9KLKpGPDAte9j3H5Ir4CIASBQAVQML6Vqxs4
Sdew+Pjxo+0izkcIqku1vLzc/u92E+uvxt4F+91Wuly8evXKthy2tLSYzs7OPROCcWXKJZ6T5ov4
CoAQBAIVQMH4loTKly9fMp81G7ipqSlxOmrx0uSRfF61otfWXL9+3fzxxx9Z32uCiL67dOlS4vIt
Li7G5iH8eWVlJeu7hoaGLNGpCTRR6WkCyObmZl75Ir4CIASBQAVQML6l2a/BJAltDx48iO3ODKcj
4agu0HyEYCAgNfkiyfdhNMEkGGeoyRluq57ei6jJLIG4cydwqCVTItTNp8Yl9vX1ZSaLNDc3R5Zp
aGgo657psyue4/JFfAVACAKBCqBgfEszdCV69AJmbWqF00um06ST61UrvskiwbX1nYSZiz7r+/BL
p8Oo+1Wvm1FXrcRWIL6EZvEGZXIFmY5Vl7OODedncHDQFBcX265pidA4cat3IaoLXelLVAYznX35
Ir4CIASBQAWAbwE2AIAQBAIVAL4F2AAAQhAIVAD4FmADAAhBAhUA4FuADQAgBAlUAIBvATYAgBAk
UAEAvgXYAABCkEAFAPgWYAMACEECFQDgW4ANACAECVQAgG8BNgCAECRQAUAy39orn9ttOj/7fOIr
AEIQCFQA+BZCEBsAQAgCgQrgaPhWeD3d8fFxU1pamlknV2v0Bmxvb5sbN26YoqIiU1FRYebn5yPT
ibvOt2/fTFtbm12rt6Sk5Lu1ikVvb69d8/fEiROmo6Mja1+S84H4CoAQJFABQEohePnyZbO6umo/
SwRKDAZ0d3eb6elp+//MzIyprKzMSwgODw+b/v5+K+g2NjZMY2Nj1v6xsTErSLV/Z2fHCr2BgYHE
5wPxFQAhSKACgDyEYCACc+2X8JP4SpJO3P66ujrbuhiwsLCQtb+2tva765SVlSU+H4ivAAhBAhUA
5CEE4/a7rYN7mY5EX3i/PrubuqqTng/EVwCEIIEKAA6IEAzvd0VfLnznA/EVACFIoAKAPRaC5eXl
eXUNr6ysZH3X0NCQ1bW7vLyctb+6utpsbm5GlsV3PhBfARCCBCoA2GMhqMkis7Oz9v8XL15EThZx
Zxt//PjRTkBx909OTpq+vr7MZI/m5uas/UNDQ5nJINr0uampKfH5QHwFQAgSqABgj4Xg169fzdWr
V63Qq6qqspM0ch0XzDZWF69aEZ8+ffpd2oODg6a4uNi+IkazhMP7u7q67Othjh8/boXk2tpaqvOB
+AqAECRQAQC+BdgAAEKQQAWAbwE2AIAQBAIVAL4F2AAAQhAIVAD4FmADAAhBIFAB4FuADQAgBIFA
BYBvATYAgBAEAhUAvgXYAABCEAhUAPgWYAMACEEgUAHgW4ANACAEgUAFgG8BNgCAEAQCFQC+BdgA
AEIQCFQA+BZgAwAIQSBQAeBbgA0AIASBQAWAbwE2AIAQBAIVAL4F2AAAQhAIVAD4FmADAAhBIFAB
4F/AswdACBKsAAAfA545AEKQgAUA++BnbEdnAwCEIEIQAIgvxBcAhCAQqAGA+AIACEEgUAMA8QUA
EIJAoAYA4gsAIASBQA0AxBcAQAgCgRoAiC8AgBAEAjUAEF8AACEIBGoAIL4AAEIQCNQAQHwBAIQg
EKgBgPgCAAhBIFADAPEFABCCQKAGAOILACAEgUANAMQXAEAIAoEaAIgvAIAQBAI1ABBfAAAhCARq
ACC+AABCkEANAEB8AQCEIIEaAID4AgAIQQI1AADxBQAQggRqAADiCwAgBA9hoGZjY2Pbrw0AEIIA
QAsPAAAgBAEAIQgAAAhBAEAIAgAAQhAAEIIAAIAQBACEIAAAIAQBACEIAAAIQQBACAIAAEIQABCC
AACAEAQAhCAAACAEAQAhCAAACEEAQAgCAABCEAD2TgCyhiwAACAEARCCCEEAAEAIAhxVMQgAAIAQ
BEAIAgAAIAQBEIIAAAAIQQCEIAAAUG9wCwAOnxgEAABACAIgBAEAABCCcDQFEdvR2QAAACEIkBGB
wDMHAACEICAIgGcPAAAIQUAIADYAAAAIQUAEADYAAIAQBEAEADYAAIAQBEAEADYAAIAQBEAEADYA
AIAQBEAEADYAAIAQBEAELC0tcaMRggAACEGAgyQCpqamzLlz58zx48dNfX29WVxczOsaOn8v87lf
wmWv0t1tOj/6fIQgAABCEBCCWbx+/do0NDSYlZUV8+3bNzM5OWkqKyt/msA6SGIFIQgAgBAEONCi
pbW11QwODiZO5+nTp+aXX34xx44dM9XV1WZubi6Tfnh921zXdL+T8GxrazMnT540JSUltmUyrkWw
t7fXnDp1ypw4ccJ0dHQkypfvXuj/8fFxU1paas9VGs+ePcvs397eNjdu3DBFRUWmoqLCzM/PR6az
m7L6ypfkfIQgAABCECCVCJAASjO2zxVKs7OzpqysLPIaPnE0PDxs+vv7rcjZ2NgwjY2NkeJqbGzM
CjYdu7OzY4XQwMBAonz5hODly5fN6uqq/aw0lFZAd3e3mZ6etv/PzMxktZamEYK+svrK5zsfIQgA
gBAESC0CJHoknNTapVavq1evms+fP0emc+bMmYww8l3DJ47q6upsi1vAwsJCpLiqra21IsjFFXtx
+fIJwUAE5tov4Re+bj5C0FdWX/l85yMEAQAQggCpRYC+v3Xrltnc3LRCRC1T6i6OQqJR50i49PT0
7EoIui1vQtePElc6Ntz9rK7cJPnajYAL53Gv0gmX1Vc+3/kIQQAAhCBAahGgMWduS5MEhm/276tX
r2w3aUtLi+ns7NwzIRgnrlxRlDZfhSgE05bPdz5CEAAAIQiQWgRcvHgx67OEoLqIk6DXzMSJofBn
zUx2v9NsZVeELi8vR6anCSBqtcwnX7sRcOXl5Xl1Dactq698vvMRggAACEGA1CJA4+q0Sexou3fv
nn2XYBQaM6cZuiI8sUICUuPtAsHiTuD4+PGjnZTh5kOvqunr68tMgGhubo4UV0NDQ5nJEtr0uamp
KVG+diMENVlE3c7ixYsXkZNFdltWX/l85yMEAQAQggB5iQCJP022UJewBMy7d+8ij1X3a1VV1f9r
7/5Bqnr/AI7PItESESESQoSIiAgNDSESNES0NzQGDg0O0SIRIuIiEQ0ShDSEgxAN0hAt0SAOQYSE
QwQRIiERiIOIyPPj8/A9l+Px/v1+Cfzl6wWXvN5zn3uvPVzenHOfe2pftVLEV4hVrjFGcWi5CLLY
NvasxbbV5xFfXXPmzJn8tSnx+cRmkTY5OZkPZRfPc3Nzs63n9V9CcHd3Ny+giTFj/FikUW+7//pa
W72+du4vBAGEIIgAzAEAIQgiAHMAQAhiQosAc8AcABCCiADMAQCEICIAcwAAIYgIwBwAQAgiAjAH
AIQgiADMAQAhCCLg2FhbW/uj25sDAHjH5EREwHGOg0ZnACnOXNKu6vYnNYiEIIAQRAieuHgVQP4O
AEIQEdDi9/HzwsJC6u3trZ2zN86h28yDBw/y+XHjXMUvXrzo6Dy+3759y+fU7erqyo916dKl9Pr1
64bPrfi3fGk1Tr3t49+dnZ3U09OTzyVctre3lwYHB2vXp6am8rl9u7u708TEhBAEEILw94ZgBNXG
xka+HhEYYdXI48eP0/T0dDo4OEibm5tpZGSkoxAcGhpKL1++zPePy9OnT3NQNgvBeuN2Mk75+vj4
eJqbmzvymiL+wvz8fA7jGHN/fz8tLi6m2dlZIQggBOHvDMEiAtuJh+Hh4UN71FZWVjoKwXpiT2Sn
IdjJOOXr6+vrea9ghF6Ify9cuFD7G8TrK24r9PX1CUEAIQh/Zwh2Eg/VvYURTZ2Ot7q6mh4+fJhu
376dBgYG2oq/euO2O071+tWrV/NevxB7FWOPaPn1VQ8tlwNTCAIIQRCC/3K8+Exhf39/ev78eXr3
7l0+vPxvQrCTcarXl5eX82cKQ3w2MO5f+H+OPiEIIAThj4bglStX0u/fv2vXv3z50nS879+/H/pd
LDLZ3t5ueHu7IdjJOPWux+KY+GxgHBYuizAsjysEAYQgCMF/vHr1Kq8ajkPCW1tbaWxs7ND25VXH
P378yIddy7dHgBWreyMiL1++3Fb8xerg+BxfrPBtZ5zq9tXXFAtAzp8/f2QhSCwkmZmZqS1Cieuj
o6NCEEAIghAMsbI2VuieO3cux1h5+2LVcRxivXjxYnrz5s2h2z98+JAXX8Q2cWh3aWmprRCMYIsv
iS6+KLrVONXtq6/p169f+baI2arJycm8xzFuj5CNw85CEEAIgggQG+YAgBAEESA2zAEAIQgnPAI6
PQ8wQhBACIIIwBwAEIIgAjAHAIQgiADMAQAhCCIAcwBACIIIwBwAEIJwXCNgbW3NH10IAghBOIkR
UP0amT/5+ALH3wlACMIxioDq44kQIQggBOGYRUCc/7c4H/Dg4GB6//59+vr1axoaGjqy7f7+furp
6Uk7Ozt5vIWFhdTb25vvG2PEuYWLxypfit89efKk7vaFqampdPr06dTd3Z0mJiZaPs96r63ZduaA
tzUAIYgIKCkH2du3b1NfX1/+eWxs7EhERfjdvXu3Nt7NmzfTxsZGvh5jxFiNHi+u37hxo+H28/Pz
efyDg4McnIuLi2l2drbl86w+VrPtzAFvawBCEBFQcvbs2bS0tHTk98vLy+n69euHfjcyMpI+ffpU
G6+IunqPUS8Em20/PDycI7CsHHGNnmd1nGbbmQPe1gCEICKgJPaaxW0RYo8ePTp0WxzGXV9fzz9/
/Pgxh2Cz8VqFYLPtY09e9ZByHN5t53mWx2m2nTngbQ1ACCICKlZXV2t7AO/fv1/7/fT0dBofH88/
37lzJz179uyPhWA5+jp9ntWxG21nDnhbAxCCiIAGPn/+fGi7ra2t1NXVlX7+/JkXcezu7v6xEIyF
Hdvb2229lurzbPTaqtuZA/4WAEIQEVDS39+fV9qG6gKOEHsCb926le7du9dR2EVAxmcC9/b22tp+
bm4uzczM5M8JxiWuj46OtvU8y+O0ej3mAABCEBHwjziMOjAwUPtKlyKiCisrK/m+1TOFtAq7WPEb
XypdfLF0q+3D5ORkOnXqVL5PrEje3Nxs63mWx2n1eswBAIQgIqBNEWOxaAQhCCAE4QRFQByijb10
Vt8KQQAhCCcsAuJzfteuXTu0SAQhCCAEQQRgDgAIQRABmAMAQhBEAOYAgBAEEYA5ACAEQQRgDgAI
QRABmAMAQhBEAOYAgBAEEYA5ACAEQQRgDgAIQRABmAMAQhBEAOYAgBAEEYA5ACAEQQRgDgAIQRAC
+L8HEIIgCPB/DiAEoXEYuJycCwCd+x9dPZuPfVdmBAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-09-05 15:09:33 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAjAAAAEACAMAAACavbxtAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-09-05 15:09:33 +0100" MODIFIED_BY="Sharath C V  Paravastu" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUgAAAHbCAIAAAAmhJSJAAAWsUlEQVR42u3dv44kSRHH8ZGQEMYY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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2013-09-05 15:25:16 +0100" MODIFIED_BY="Heather Maxwell">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2013-09-05 15:25:16 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE MODIFIED="2010-02-16 14:34:05 +0000" MODIFIED_BY="Heather Maxwell">Comment by Dr Aaron Tejani</TITLE>
<DATE_SUBMITTED>
<DATE DAY="1" MONTH="2" YEAR="2010"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-09-05 15:25:13 +0100" MODIFIED_BY="Heather Maxwell">
<P>Paravastu et al have provided insight into an important topic, and I thank them for their work. I do however want to clarify some statements made regarding what is known about beta blockers. The authors state that "beta blockers have been shown to reduce mortality in people with hypertension and coronary artery disease." The first part of this statement is not correct. Wiysonge 2009 found that for hypertension, "the risk of all-cause mortality was not different between first-line beta-blockers and placebo (RR 0.99, 95% CI 0.88 to 1.11, I<SUP>2</SUP> = 0%), diuretics or RAS inhibitors, but was higher for beta blockers compared with CCBs (RR 1.07, 95% CI 1.00 to 1.14, I<SUP>2</SUP> = 2.2%; ARI = 0.5%, NNH = 200)." In addition, Wright 2009 found that beta blockers, when used first line for hypertension, "reduced stroke (RR 0.83, 95% CI 0.72, 0.97) and CVS (RR 0.89, 95% CI 0.81, 0.98) but not CHD (RR 0.90, 95% CI 0.78, 1.03) or mortality (RR 0.96, 95% CI 0.86, 1.07)."<BR/> <BR/>The second part of the authors' statement mentioned above is also not entirely reflective of evidence for beta blockers. Beta blockers have not been shown to reduce mortality in ALL coronary artery disease patients. It is important to clarify that beta blockers have been shown to reduce mortality only in the setting of an acute myocardial infarction (Freemantle 1999, CAPRICORN 2001).<BR/>
<BR/>Finally, it was not mentioned that beta blockers have been shown to reduce mortality in patients with heart failure.(Brophy 2001).<BR/>
<BR/>Aaron M Tejani<BR/>Cochrane Hypertension Review Group<BR/>
<BR/>Brophy JM, Joesph L, Rouleau JL. Beta blockers in congestive heart failure: a bayesian meta analysis. Ann Intern Med 2001;134:550-560.<BR/>
<BR/>CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001;357:1385-1390.<BR/>
<BR/>Fremantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-1737.<BR/>
<BR/>Wiysonge CSU, Bradley HA, Mayosi BM, Maroney RT, Mbewu A, Opie L, et al. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002003. DOI: 10.1002/14651858.CD002003.pub2.<BR/>
<BR/>Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD001841. DOI: 10.1002/14651858.CD001841.pub2.<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2013-09-05 15:25:16 +0100" MODIFIED_BY="Heather Maxwell">
<P>On behalf of all authors, I would like to thank Aaron Tejani for highlighting the above issues. We have looked at the latest evidence on the role of beta blocker use in hypertension and have incorporated the necessary changes in the manuscript.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2010-02-16 14:43:31 +0000" MODIFIED_BY="Heather Maxwell">
<P>Feedback: Aaron M Tejani, Cochrane Hypertension Review Group</P>
<P>Reply: Mr Sharath Paravastu, Contact author of the review, Cochrane Peripheral Vascular Diseases Group</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-08-07 07:56:32 +0100" MODIFIED_BY="Heather  Maxwell">
<APPENDIX ID="APP-01" MODIFIED="2013-08-07 07:56:32 +0100" MODIFIED_BY="Heather  Maxwell" NO="1">
<TITLE MODIFIED="2008-07-03 11:04:47 +0100" MODIFIED_BY="Heather  Maxwell">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-08-07 07:56:32 +0100" MODIFIED_BY="Heather  Maxwell">
<TABLE COLS="3" ROWS="44">
<TR>
<TD>
<P>#1</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>893</P>
</TD>
</TR>
<TR>
<TD>
<P>#2</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriolosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>#3</P>
</TD>
<TD>
<P>MeSH descriptor: [Arteriosclerosis Obliterans] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>71</P>
</TD>
</TR>
<TR>
<TD>
<P>#4</P>
</TD>
<TD>
<P>MeSH descriptor: [Atherosclerosis] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>382</P>
</TD>
</TR>
<TR>
<TD>
<P>#5</P>
</TD>
<TD>
<P>MeSH descriptor: [Arterial Occlusive Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>755</P>
</TD>
</TR>
<TR>
<TD>
<P>#6</P>
</TD>
<TD>
<P>MeSH descriptor: [Intermittent Claudication] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>711</P>
</TD>
</TR>
<TR>
<TD>
<P>#7</P>
</TD>
<TD>
<P>MeSH descriptor: [Ischemia] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>753</P>
</TD>
</TR>
<TR>
<TD>
<P>#8</P>
</TD>
<TD>
<P>MeSH descriptor: [Peripheral Vascular Diseases] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>2150</P>
</TD>
</TR>
<TR>
<TD>
<P>#9</P>
</TD>
<TD>
<P>MeSH descriptor: [Vascular Diseases] this term only</P>
</TD>
<TD ALIGN="RIGHT">
<P>381</P>
</TD>
</TR>
<TR>
<TD>
<P>#10</P>
</TD>
<TD>
<P>MeSH descriptor: [Leg] explode all trees and with qualifiers: [Blood supply - BS]</P>
</TD>
<TD ALIGN="RIGHT">
<P>1075</P>
</TD>
</TR>
<TR>
<TD>
<P>#11</P>
</TD>
<TD>
<P>MeSH descriptor: [Femoral Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>720</P>
</TD>
</TR>
<TR>
<TD>
<P>#12</P>
</TD>
<TD>
<P>MeSH descriptor: [Popliteal Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>250</P>
</TD>
</TR>
<TR>
<TD>
<P>#13</P>
</TD>
<TD>
<P>MeSH descriptor: [Iliac Artery] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>151</P>
</TD>
</TR>
<TR>
<TD>
<P>#14</P>
</TD>
<TD>
<P>MeSH descriptor: [Tibial Arteries] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>29</P>
</TD>
</TR>
<TR>
<TD>
<P>#15</P>
</TD>
<TD>
<P>(atherosclero* or arteriosclero* or PVD or PAOD or PAD)</P>
</TD>
<TD ALIGN="RIGHT">
<P>17195</P>
</TD>
</TR>
<TR>
<TD>
<P>#16</P>
</TD>
<TD>
<P>(arter*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>4872</P>
</TD>
</TR>
<TR>
<TD>
<P>#17</P>
</TD>
<TD>
<P>(vascular) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1378</P>
</TD>
</TR>
<TR>
<TD>
<P>#18</P>
</TD>
<TD>
<P>(vein*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>713</P>
</TD>
</TR>
<TR>
<TD>
<P>#19</P>
</TD>
<TD>
<P>(veno*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>976</P>
</TD>
</TR>
<TR>
<TD>
<P>#20</P>
</TD>
<TD>
<P>(peripher*) near (*occlus* or steno* or obstuct* or lesio* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1358</P>
</TD>
</TR>
<TR>
<TD>
<P>#21</P>
</TD>
<TD>
<P>peripheral near/3 dis*</P>
</TD>
<TD ALIGN="RIGHT">
<P>3243</P>
</TD>
</TR>
<TR>
<TD>
<P>#22</P>
</TD>
<TD>
<P>arteriopathic</P>
</TD>
<TD ALIGN="RIGHT">
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>#23</P>
</TD>
<TD>
<P>(claudic* or hinken*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1436</P>
</TD>
</TR>
<TR>
<TD>
<P>#24</P>
</TD>
<TD>
<P>(isch* or CLI)</P>
</TD>
<TD ALIGN="RIGHT">
<P>16827</P>
</TD>
</TR>
<TR>
<TD>
<P>#25</P>
</TD>
<TD>
<P>dysvascular*</P>
</TD>
<TD ALIGN="RIGHT">
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>#26</P>
</TD>
<TD>
<P>leg near/4 (obstruct* or occlus* or steno* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>176</P>
</TD>
</TR>
<TR>
<TD>
<P>#27</P>
</TD>
<TD>
<P>limb near/4 (obstruct* or occlus* or steno* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>228</P>
</TD>
</TR>
<TR>
<TD>
<P>#28</P>
</TD>
<TD>
<P>(lower near/3 extrem*) near/4 (obstruct* or occlus* or steno* or block* or obliter*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>137</P>
</TD>
</TR>
<TR>
<TD>
<P>#29</P>
</TD>
<TD>
<P>(aort* or iliac or femoral or popliteal or femoro* or fempop* or crural) near/3 (obstruct* or occlus*)</P>
</TD>
<TD ALIGN="RIGHT">
<P>326</P>
</TD>
</TR>
<TR>
<TD>
<P>#30</P>
</TD>
<TD>
<P>#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29</P>
</TD>
<TD ALIGN="RIGHT">
<P>39632</P>
</TD>
</TR>
<TR>
<TD>
<P>#31</P>
</TD>
<TD>
<P>MeSH descriptor: [Adrenergic beta-Antagonists] explode all trees</P>
</TD>
<TD ALIGN="RIGHT">
<P>3978</P>
</TD>
</TR>
<TR>
<TD>
<P>#32</P>
</TD>
<TD>
<P>(betablocker* or beta-blocker*):ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>4040</P>
</TD>
</TR>
<TR>
<TD>
<P>#33</P>
</TD>
<TD>
<P>(adrenergic near/3 (antagonist* or block*)):ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>6714</P>
</TD>
</TR>
<TR>
<TD>
<P>#34</P>
</TD>
<TD>
<P>(beta* near/3 block*):ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>7168</P>
</TD>
</TR>
<TR>
<TD>
<P>#35</P>
</TD>
<TD>
<P>acebutolol or atenolol or Tenormin or alprenolol:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>3067</P>
</TD>
</TR>
<TR>
<TD>
<P>#36</P>
</TD>
<TD>
<P>betaxolol or bisoprolol or bupranolol:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>832</P>
</TD>
</TR>
<TR>
<TD>
<P>#37</P>
</TD>
<TD>
<P>carvedilol or Coreg or carteolol or celiprolol:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>976</P>
</TD>
</TR>
<TR>
<TD>
<P>#38</P>
</TD>
<TD>
<P>esmolol or labetalol or Normodyne or Trandate:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>834</P>
</TD>
</TR>
<TR>
<TD>
<P>#39</P>
</TD>
<TD>
<P>metoprolol or nadolol or nebivolol:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>2644</P>
</TD>
</TR>
<TR>
<TD>
<P>#40</P>
</TD>
<TD>
<P>oxprenolol or penbutolol or pindolol:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>1240</P>
</TD>
</TR>
<TR>
<TD>
<P>#41</P>
</TD>
<TD>
<P>Visken or practolol or propranolol or Inderal:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>4255</P>
</TD>
</TR>
<TR>
<TD>
<P>#42</P>
</TD>
<TD>
<P>sotalol or timolol:ti,ab,kw (Word variations have been searched)</P>
</TD>
<TD ALIGN="RIGHT">
<P>2051</P>
</TD>
</TR>
<TR>
<TD>
<P>#43</P>
</TD>
<TD>
<P>#31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42</P>
</TD>
<TD ALIGN="RIGHT">
<P>16792</P>
</TD>
</TR>
<TR>
<TD>
<P>#44</P>
</TD>
<TD>
<P>#30 and #43 in Trials</P>
</TD>
<TD ALIGN="RIGHT">
<P>1813</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies included in qualitative synthesis &lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;6 studies included in previous version or review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 NEW studies included &lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1703 records screened by titles/abstract&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1703 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1813 records identified through searching CENTRAL&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;11 additional records identified from Specialised Register&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1692 records not relevant for this review&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;4 NEW studies excluded, with reasons and a further 7 reports of 4 studies deemed not relevant&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>